

14. SUMMARY TABLES AND FIGURES

1

Protocol: CDISCPILOT01
Population: All Subjects

Page 1 of 1 3

2

Table 14-1.01
Summary of Populations

	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)
Intent-To-Treat (ITT)	86 (100%)	84 (100%)	84 (100%)	254 (100%)
Safety	86 (100%)	84 (100%)	84 (100%)	254 (100%)
Efficacy	79 (92%)	81 (96%)	74 (88%)	234 (92%)
Complete Week 24	60 (70%)	28 (33%)	30 (36%)	118 (46%)
Complete Study	58 (67%)	25 (30%)	27 (32%)	110 (43%)

after rand
use one dose
itt
complete 24w
complete whole

4 NOTE: N in column headers represents number of subjects entered in study (i.e., signed informed consent). The ITT population includes all subjects randomized. The Safety population includes all randomized subjects known to have taken at least one dose of randomized study drug. The Efficacy population includes all subjects in the safety population who also have at least one post-baseline ADAS-Cog and CIBIC+ assessment.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl1.sas

21:02 Monday, June 26, 2006

5

6

Protocol: CDISCPIL0T01
Population: Intent-to-Treat

Page 1 of 1

Table 14-1.02
Summary of End of Study Data

	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
Completion Status:					
Completed Week 24	60 (70%)	28 (33%)	30 (36%)	118 (46%)	<.0001
Early Termination (prior to Week 24)	26 (30%)	56 (67%)	54 (64%)	136 (54%)	
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Reason for Early Termination (prior to Week 24):					
Adverse Event	8 (9%)	44 (52%)	39 (46%)	91 (36%)	<.0001
Death	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
Lack of Efficacy[2]	3 (3%)	0 (0%)	1 (1%)	4 (2%)	0.3281
Lost to Follow-up	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
Subject decided to withdraw	9 (10%)	8 (10%)	8 (10%)	25 (10%)	
Physician decided to withdraw subject	1 (1%)	0 (0%)	2 (2%)	3 (1%)	
Protocol criteria not met	1 (1%)	0 (0%)	2 (2%)	3 (1%)	
Protocol violation	1 (1%)	1 (1%)	1 (1%)	3 (1%)	
Sponsor decision	1 (1%)	2 (2%)	1 (1%)	4 (2%)	
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	

[1] Fisher's exact test.

[2] Based on either patient/caregiver perception or physician perception.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl2.sas

21:02 Monday, June 26, 2006

Table 14-1.03
Summary of Number of Subjects By Site

Pooled Id	Site Id	Placebo (N=86)			Xanomeline Low Dose (N=84)			Xanomeline High Dose (N=84)			Total (N=254)		
		ITT	Eff	Com	ITT	Eff	Com	ITT	Eff	Com	ITT	Eff	Com
701	701	14	14	11	13	13	5	14	14	7	41	41	23
703	703	6	5	4	6	5	1	6	5	2	18	15	7
704	704	9	9	5	8	7	3	8	8	0	25	24	8
705	705	5	3	2	5	5	3	6	4	1	16	12	6
708	708	9	9	7	8	8	2	8	5	2	25	22	11
709	709	7	7	5	7	6	2	7	7	3	21	20	10
710	710	11	8	6	10	10	2	10	8	5	31	26	13
713	713	3	3	3	3	3	2	3	2	2	9	8	7
716	716	8	8	7	8	8	3	8	8	3	24	24	13
718	718	4	4	3	5	5	1	4	4	1	13	13	5
900	702	0	0	0	1	1	0	0	0	0	1	1	0
900	706	1	1	1	1	1	0	1	1	0	3	3	1
900	707	1	1	1	1	1	0	0	0	0	2	2	1
900	711	1	1	1	1	1	0	2	1	0	4	3	1
900	714	2	2	2	2	2	1	2	2	1	6	6	4
900	715	3	2	2	3	3	1	2	2	0	8	7	3
900	717	2	2	0	2	2	2	3	3	3	7	7	5
TOTAL		86	79	60	84	81	28	84	74	30	254	234	118

Note: ITT: Number of subjects in the ITT population, Eff: Number of subjects in the Efficacy population;
Com: Number of subjects completing Week 24.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl4.sas

21:02 Monday, June 26, 2006

Table 14-2.01
Summary of Demographic and Baseline Characteristics

		Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
Age (y)	n	86	84	84	254	0.5934
	Mean	75.2	75.7	74.4	75.1	
	SD	8.59	8.29	7.89	8.25	
	Median	76.0	77.5	76.0	77.0	
	Min	52.0	51.0	56.0	51.0	
	Max	89.0	88.0	88.0	89.0	
	<65 yrs	14 (16%)	8 (10%)	11 (13%)	33 (13%)	0.1439
	65-80 yrs	42 (49%)	47 (56%)	55 (65%)	144 (57%)	
	>80 yrs	30 (35%)	29 (35%)	18 (21%)	77 (30%)	
Sex	n	86	84	84	254	0.1409
	Male	33 (38%)	34 (40%)	44 (52%)	111 (44%)	
	Female	53 (62%)	50 (60%)	40 (48%)	143 (56%)	
Race (Origin)	n	86	84	84	254	0.6477
	Caucasian	75 (87%)	72 (86%)	71 (85%)	218 (86%)	
	African Descent	8 (9%)	6 (7%)	9 (11%)	23 (9%)	
	Hispanic	3 (3%)	6 (7%)	3 (4%)	12 (5%)	
	Other	0	0	1 (1%)	1 (<1%)	
MMSE	n	86	84	84	254	0.5947
	Mean	18.0	17.9	18.5	18.1	
	SD	4.27	4.22	4.16	4.21	
	Median	19.5	18.0	20.0	19.0	

[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-square test for categorical variables.

NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first definite symptoms of *Alzheimer's disease*.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas

21:02 Monday, June 26, 2006

Table 14-2.01
Summary of Demographic and Baseline Characteristics

		Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
	Min	10.0	10.0	10.0	10.0	
	Max	23.0	24.0	24.0	24.0	
Duration of disease	n	86	84	84	254	0.1530
	Mean	42.7	48.7	40.5	43.9	
	SD	30.24	29.58	24.69	28.40	
	Median	35.3	40.3	36.0	36.3	
	Min	7.2	7.8	2.2	2.2	
	Max	183.1	130.8	135.0	183.1	
	<12 months	5 (6%)	3 (4%)	4 (5%)	12 (5%)	0.7885
	>=12 months	81 (94%)	81 (96%)	80 (95%)	242 (95%)	
Years of education	n	86	84	84	254	0.3875
	Mean	12.6	13.2	12.5	12.8	
	SD	2.95	4.15	2.92	3.38	
	Median	12.0	12.0	12.0	12.0	
	Min	6.0	3.0	6.0	3.0	
	Max	21.0	24.0	20.0	24.0	
Baseline weight (kg)	n	86	83	84	253	0.0030
	Mean	62.8	67.3	70.0	66.6	
	SD	12.77	14.12	14.65	14.13	
	Median	60.6	64.9	69.2	66.7	
	Min	34.0	45.4	41.7	34.0	
	Max	86.2	106.1	108.0	108.0	

[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-square test for categorical variables.

NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first definite symptoms of Alzheimer's disease.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas

21:02 Monday, June 26, 2006

Table 14-2.01
Summary of Demographic and Baseline Characteristics

		Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value [1]
Baseline height (cm)	n	86	84	84	254	0.1262
	Mean	162.6	163.4	165.8	163.9	
	SD	11.52	10.42	10.13	10.76	
	Median	162.6	162.6	165.1	162.9	
	Min	137.2	135.9	146.1	135.9	
	Max	185.4	195.6	190.5	195.6	
Baseline BMI	n	86	83	84	253	0.0133
	Mean	23.6	25.1	25.3	24.7	
	SD	3.67	4.27	4.16	4.09	
	Median	23.4	24.3	24.8	24.2	
	Min	15.1	17.7	13.7	13.7	
	Max	33.3	40.1	34.5	40.1	
	<25	59 (69%)	47 (56%)	44 (52%)	150 (59%)	0.2326
	25-<30	21 (24%)	27 (32%)	28 (33%)	76 (30%)	
	>=30	6 (7%)	10 (12%)	12 (14%)	28 (11%)	

[1] P-values are results of ANOVA treatment group comparison for continuous variable and Pearson's chi-square test for categorical variables.

NOTE: Duration of disease is computed as months between date of enrollment and date of onset of the first definite symptoms of Alzheimer's disease.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl3.sas

21:02 Monday, June 26, 2006

Table 14-3.01

Primary Endpoint Analysis: ADAS Cog (11) - Change from Baseline to Week 24 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	24.1 (12.19)	24.4 (12.92)	21.3 (11.74)
Median (Range)	21.0 (5;61)	21.0 (5;57)	18.0 (3;57)
Week 24			
n	79	81	74
Mean (SD)	26.7 (13.79)	26.4 (13.18)	22.8 (12.48)
Median (Range)	24.0 (5;62)	25.0 (6;62)	20.0 (3;62)
Change from Baseline			
n	79	81	74
Mean (SD)	2.5 (5.80)	2.0 (5.55)	1.5 (4.26)
Median (Range)	2.0 (-11;16)	2.0 (-11;17)	1.0 (-7;13)
p-value (Dose Response) [1] [2]			0.245
p-value (Xan - Placebo) [1] [3]		0.569	0.233
Diff of LS Means (SE)		-0.5 (0.82)	-1.0 (0.84)
95% CI		(-2.1;1.1)	(-2.7;0.7)
p-value (Xan High - Xan Low) [1] [3]			0.520
Diff of LS Means (SE)			-0.5 (0.84)
95% CI			(-2.2;1.1)

dose response
for change

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Table 14-3.02
Primary Endpoint Analysis: CIBIC+ - Summary at Week 24 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Week 24			
n	79	81	74
Mean (SD)	4.3 (0.77)	4.2 (0.79)	4.3 (0.81)
Median (Range)	4.0 (2;6)	4.0 (2;6)	4.0 (3;6)
p-value(Dose Response) [1] [2]			0.960
p-value(Xan - Placebo) [1] [3]		0.489	0.799
Diff of LS Means (SE)		-0.1 (0.13)	0.0 (0.13)
95% CI		(-0.3;0.2)	(-0.2;0.3)
p-value(Xan High - Xan Low) [1] [3]			0.349
Diff of LS Means (SE)			0.1 (0.13)
95% CI			(-0.1;0.4)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Table 14-3.03
ADAS Cog (11) - Change from Baseline to Week 8 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	24.1 (12.19)	24.4 (12.92)	21.3 (11.74)
Median (Range)	21.0 (5;61)	21.0 (5;57)	18.0 (3;57)
Week 8			
n	79	81	74
Mean (SD)	25.0 (13.10)	26.2 (12.98)	22.3 (12.41)
Median (Range)	22.0 (5;62)	25.0 (5;62)	19.0 (2;62)
Change from Baseline			
n	79	81	74
Mean (SD)	0.8 (4.81)	1.8 (4.14)	1.0 (3.62)
Median (Range)	1.0 (-12;16)	2.0 (-12;14)	1.0 (-8;13)
p-value(Dose Response) [1][2]			0.497
p-value(Xan - Placebo) [1][3]		0.099	0.751
Diff of LS Means (SE)		1.1 (0.65)	0.2 (0.67)
95% CI		(-0.2;2.4)	(-1.1;1.5)
p-value(Xan High - Xan Low) [1][3]			0.195
Diff of LS Means (SE)			-0.9 (0.66)
95% CI			(-2.2;0.4)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Table 14-3.04
CIBIC+ - Summary at Week 8 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Week 8			
n	77	81	73
Mean (SD)	3.9 (0.73)	4.0 (0.72)	4.1 (0.75)
Median (Range)	4.0 (2;6)	4.0 (2;6)	4.0 (2;6)
p-value(Dose Response) [1][2]			0.167
p-value(Xan - Placebo) [1][3]		0.754	0.128
Diff of LS Means (SE)		0.0 (0.12)	0.2 (0.12)
95% CI		(-0.2;0.3)	(-0.1;0.4)
p-value(Xan High - Xan Low) [1][3]			0.218
Diff of LS Means (SE)			0.1 (0.12)
95% CI			(-0.1;0.4)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Table 14-3.05
ADAS Cog (11) - Change from Baseline to Week 16 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	24.1 (12.19)	24.4 (12.92)	21.3 (11.74)
Median (Range)	21.0 (5;61)	21.0 (5;57)	18.0 (3;57)
Week 16			
n	79	81	74
Mean (SD)	26.1 (14.16)	26.0 (13.05)	22.5 (12.33)
Median (Range)	23.0 (5;63)	25.0 (5;62)	20.0 (4;62)
Change from Baseline			
n	79	81	74
Mean (SD)	2.0 (5.89)	1.6 (4.10)	1.2 (4.33)
Median (Range)	2.0 (-17;23)	2.0 (-9;14)	1.0 (-11;13)
p-value(Dose Response) [1][2]			0.412
p-value(Xan - Placebo) [1][3]		0.724	0.392
Diff of LS Means (SE)		-0.3 (0.77)	-0.7 (0.79)
95% CI		(-1.8;1.2)	(-2.2;0.9)
p-value(Xan High - Xan Low) [1][3]			0.606
Diff of LS Means (SE)			-0.4 (0.78)
95% CI			(-1.9;1.1)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Table 14-3.06
CIBIC+ - Summary at Week 16 - LOCF

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Week 16			
n	79	81	74
Mean (SD)	4.2 (0.70)	4.0 (0.77)	4.0 (0.75)
Median (Range)	4.0 (3;6)	4.0 (2;6)	4.0 (2;5)
p-value(Dose Response) [1][2]			0.214
p-value(Xan - Placebo) [1][3]		0.219	0.272
Diff of LS Means (SE)		-0.1 (0.12)	-0.1 (0.12)
95% CI		(-0.4;0.1)	(-0.4;0.1)
p-value(Xan High - Xan Low) [1][3]			0.916
Diff of LS Means (SE)			0.0 (0.12)
95% CI			(-0.2;0.2)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPILOT01

Page 1 of 1

Population: Completers

Table 14-3.07

ADAS Cog (11) - Change from Baseline to Week 24 - Completers at Wk 24-Observed Cases-Windowed

	Placebo (N=60)	Xanomeline Low Dose (N=28)	Xanomeline High Dose (N=30)
Baseline			
n	59	27	30
Mean (SD)	23.2 (11.74)	24.0 (13.89)	20.5 (11.50)
Median (Range)	21.0 (5;51)	20.0 (5;57)	18.0 (3;49)
Week 24			
n	59	27	30
Mean (SD)	25.3 (13.32)	24.1 (11.87)	21.8 (12.60)
Median (Range)	23.0 (5;58)	22.0 (8;51)	18.5 (3;44)
Change from Baseline			
n	59	27	30
Mean (SD)	2.1 (5.89)	0.1 (5.86)	1.3 (4.51)
Median (Range)	2.0 (-11;16)	1.0 (-11;12)	1.0 (-7;13)
p-value(Dose Response) [1][2]			0.234
p-value(Xan - Placebo) [1][3]		0.105	0.461
Diff of LS Means (SE)		-2.1 (1.26)	-0.9 (1.22)
95% CI		(-4.6;0.4)	(-3.3;1.5)
p-value(Xan High - Xan Low) [1][3]			0.430
Diff of LS Means (SE)			1.2 (1.47)
95% CI			(-1.8;4.1)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Note that only assessments falling within the assessment window are included in the summary for a visit.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPilot01

Page 1 of 1

Population: Efficacy

Table 14-3.08

ADAS Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF

	Placebo (N=33)	Xanomeline Low Dose (N=34)	Xanomeline High Dose (N=39)
Baseline			
n	33	34	39
Mean (SD)	22.8 (13.45)	23.3 (14.03)	20.8 (11.11)
Median (Range)	19.0 (5;61)	21.5 (7;57)	17.0 (3;51)
Week 24			
n	33	34	39
Mean (SD)	24.7 (13.89)	25.7 (14.72)	22.7 (12.32)
Median (Range)	20.0 (5;62)	24.0 (6;57)	21.0 (3;51)
Change from Baseline			
n	33	34	39
Mean (SD)	1.9 (6.14)	2.5 (5.61)	1.8 (3.77)
Median (Range)	1.0 (-11;16)	1.0 (-6;14)	1.0 (-7;13)
p-value(Dose Response) [1][2]			0.873
p-value(Xan - Placebo) [1][3]		0.712	0.915
Diff of LS Means (SE)		0.5 (1.30)	0.1 (1.25)
95% CI		(-2.1;3.1)	(-2.4;2.6)
p-value(Xan High - Xan Low) [1][3]			0.783
Diff of LS Means (SE)			-0.3 (1.26)
95% CI			(-2.9;2.2)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Table 14-3.09
ADAS Cog (11) - Change from Baseline to Week 24 in Female Subjects - LOCF

	Placebo (N=46)	Xanomeline Low Dose (N=47)	Xanomeline High Dose (N=35)
Baseline			
n	46	47	35
Mean (SD)	25.1 (11.25)	25.2 (12.15)	21.8 (12.54)
Median (Range)	23.5 (5;51)	21.0 (5;55)	18.0 (5;57)
Week 24			
n	46	47	35
Mean (SD)	28.1 (13.70)	26.9 (12.09)	22.9 (12.84)
Median (Range)	24.0 (8;59)	25.0 (8;62)	19.0 (4;62)
Change from Baseline			
n	46	47	35
Mean (SD)	3.0 (5.57)	1.7 (5.54)	1.1 (4.77)
Median (Range)	3.0 (-8;16)	2.0 (-11;17)	0.0 (-7;13)
p-value(Dose Response) [1][2]			0.094
p-value(Xan - Placebo) [1][3]		0.160	0.135
Diff of LS Means (SE)		-1.6 (1.10)	-1.8 (1.20)
95% CI		(-3.7;0.6)	(-4.2;0.6)
p-value(Xan High - Xan Low) [1][3]			0.843
Diff of LS Means (SE)			-0.2 (1.21)
95% CI			(-2.6;2.2)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPilot01

Page 1 of 1

Population: Efficacy

Table 14-3.10
ADAS Cog (11) - Mean and Mean Change from Baseline over Time

										---Change from baseline---				
		nc	Mean	Std	Med.	Min.	Max.	Bsln Mean	Bsln Std	Mean	Std	Med.	Min.	Max.
Placebo	Baseline	79	24.1	12.19	21.0	5	61							
	Week 8 (Windowed)	79	25.0	13.10	22.0	5	62	24.1	12.19	0.8	4.81	1.0	-12	16
	Week 16 (Windowed)	68	25.1	13.42	21.0	5	63	23.4	11.32	1.7	5.92	2.0	-17	23
	Week 24 (Windowed)	65	25.7	13.90	23.0	5	59	23.6	12.13	2.1	5.99	2.0	-11	16
	Week 8 LOCF	79	25.0	13.10	22.0	5	62	24.1	12.19	0.8	4.81	1.0	-12	16
	Week 16 LOCF	79	26.1	14.16	23.0	5	63	24.1	12.19	2.0	5.89	2.0	-17	23
	Week 24 LOCF	79	26.7	13.79	24.0	5	62	24.1	12.19	2.5	5.80	2.0	-11	16
Xan.Low	Baseline	81	24.4	12.92	21.0	5	57							
	Week 8 (Windowed)	81	26.2	12.98	25.0	5	62	24.4	12.92	1.8	4.14	2.0	-12	14
	Week 16 (Windowed)	42	26.2	12.23	25.0	8	53	25.0	12.52	1.2	4.33	1.0	-8	13
	Week 24 (Windowed)	49	25.6	13.81	24.0	7	57	24.4	13.76	1.3	6.05	1.0	-11	17
	Week 8 LOCF	81	26.2	12.98	25.0	5	62	24.4	12.92	1.8	4.14	2.0	-12	14
	Week 16 LOCF	81	26.0	13.05	25.0	5	62	24.4	12.92	1.6	4.10	2.0	-9	14
	Week 24 LOCF	81	26.4	13.18	25.0	6	62	24.4	12.92	2.0	5.55	2.0	-11	17
Xan.High	Baseline	74	21.3	11.74	18.0	3	57							
	Week 8 (Windowed)	74	22.3	12.41	19.0	2	62	21.3	11.74	1.0	3.62	1.0	-8	13
	Week 16 (Windowed)	40	21.9	12.39	19.5	4	49	21.1	11.79	0.8	4.92	1.0	-11	10
	Week 24 (Windowed)	41	21.8	12.38	19.0	3	45	20.1	11.13	1.7	4.74	1.0	-7	13
	Week 8 LOCF	74	22.3	12.41	19.0	2	62	21.3	11.74	1.0	3.62	1.0	-8	13
	Week 16 LOCF	74	22.5	12.33	20.0	4	62	21.3	11.74	1.2	4.33	1.0	-11	13
	Week 24 LOCF	74	22.8	12.48	20.0	3	62	21.3	11.74	1.5	4.26	1.0	-7	13

Protocol: CDISCPILOT01

Page 1 of 1

Population: Efficacy

Table 14-3.11

ADAS Cog (11) - Repeated Measures Analysis of Change from Baseline to Week 24

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
LS Means (SE)	1.6 (0.49)	1.5 (0.52)	1.1 (0.56)
p-value(Xan - Placebo)		0.955	0.556
Diff of LS Means (SE)		-0.0 (0.70)	-0.4 (0.72)
95% CI		(-1.4;1.3)	(-1.9;1.0)
p-value(Xan High - Xan Low)			0.606
Diff of LS Means (SE)			-0.4 (0.75)
95% CI			(-1.9;1.1)

Note: The change from baseline is calculated as the post-baseline score minus the baseline score. The covariates included in the MMRM model are treatment, site group, time and treatment by time interaction, baseline ADAS-Cog (11) score, and baseline ADAS-Cog (11) score by time interaction.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff_mmrms.sas

21:06 Monday, June 26, 2006

Table 14-3.12
Mean NPI-X Total Score from Week 4 through Week 24 - Windowed

	Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)
Baseline			
n	79	81	74
Mean (SD)	9.5 (12.10)	8.7 (9.82)	11.9 (13.70)
Median (Range)	5.0 (0;66)	4.0 (0;32)	8.0 (0;61)
Mean of Weeks 4-24			
n	78	75	69
Mean (SD)	9.3 (11.18)	9.1 (12.10)	9.6 (11.60)
Median (Range)	5.5 (0;65)	3.8 (0;51)	4.4 (0;46)
p-value(Dose Response) [1][2]			0.637
p-value(Xan - Placebo) [1][3]		0.760	0.517
Diff of LS Means (SE)		0.3 (1.13)	-0.7 (1.15)
95% CI		(-1.9;2.6)	(-3.0;1.5)
p-value(Xan High - Xan Low) [1][3]			0.350
Diff of LS Means (SE)			-1.1 (1.17)
95% CI			(-3.4;1.2)

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.

[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPILOT01

Page 1 of 1

Population: Efficacy

Table 14-3.13
CIBIC+ - Categorical Analysis - LOCF

Assessment		Placebo (N=79)	Xanomeline Low Dose (N=81)	Xanomeline High Dose (N=74)	p-value [1]
Week 8	n	77	81	73	0.2727
	Marked improvement	0	0	0	
	Moderate improvement	1 (1%)	2 (2%)	1 (1%)	
	Minimal improvement	19 (25%)	16 (20%)	13 (18%)	
	No Change	45 (58%)	48 (59%)	38 (52%)	
	Minimal worsening	10 (13%)	14 (17%)	20 (27%)	
	Moderate worsening	2 (3%)	1 (1%)	1 (1%)	
	Marked worsening	0	0	0	
Week 16	n	79	81	74	0.4003
	Marked improvement	0	0	0	
	Moderate improvement	0	3 (4%)	2 (3%)	
	Minimal improvement	12 (15%)	12 (15%)	13 (18%)	
	No Change	41 (52%)	46 (57%)	39 (53%)	
	Minimal worsening	25 (32%)	19 (23%)	20 (27%)	
	Moderate worsening	1 (1%)	1 (1%)	0	
	Marked worsening	0	0	0	
Week 24	n	79	81	74	0.6180
	Marked improvement	0	0	0	
	Moderate improvement	1 (1%)	1 (1%)	0	
	Minimal improvement	9 (11%)	14 (17%)	11 (15%)	
	No Change	38 (48%)	37 (46%)	33 (45%)	
	Minimal worsening	28 (35%)	27 (33%)	25 (34%)	
	Moderate worsening	3 (4%)	2 (2%)	5 (7%)	
	Marked worsening	0	0	0	

[1] Overall comparison of treatments using CMH test (Pearson Chi-Square), controlling for site group.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff_cat.sas

21:06 Monday, June 26, 2006

Protocol: CDISCPILOT01

Page 1 of 1

Population: Safety

Table 14-4.01

Summary of Planned Exposure to Study Drug, as of End of Study

		Completers at Week 24			Safety Population [1]		
		Placebo (N=60)	Xanomeline Low Dose (N=28)	Xanomeline High Dose (N=30)	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)
Average daily dose (mg)	n	60	28	30	86	84	84
	mean	0.0	54.0	77.0	0.0	54.0	71.6
	std	0.00	0.00	0.58	0.00	0.00	8.11
	median	0.0	54.0	76.9	0.0	54.0	75.1
	min	0.0	54.0	76.1	0.0	54.0	54.0
	max	0.0	54.0	78.6	0.0	54.0	78.6
Cumulative dose at end of study [2]	n	60	28	30	86	84	84
	mean	0.0	9918.6	14089.5	0.0	5347.3	7551.0
	std	0.00	603.84	481.01	0.00	3680.35	5531.04
	median	0.0	9936.0	14080.5	0.0	4455.0	5778.0
	min	0.0	7884.0	12960.0	0.0	108.0	54.0
	max	0.0	11448.0	15417.0	0.0	11448.0	15417.0

[1] Includes completers and early terminators.

[2] End of Study refers to week 26/Early Termination.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\adsl12.sas

21:02 Monday, June 26, 2006

Protocol: CDISCILOT01
Population: Safety

Page 1 of 16

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Low Dose vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
ANY BODY SYSTEM	65 (75.6%)	[281]	77 (91.7%)	[412]	76 (90.5%)	[433]	0.007*	0.014*
CARDIAC DISORDERS	12 (14.0%)	[26]	13 (15.5%)	[30]	15 (17.9%)	[30]	0.831	0.534
SINUS BRADYCARDIA	2 (2.3%)	[2]	7 (8.3%)	[10]	8 (9.5%)	[12]	0.097*	0.056*
MYOCARDIAL INFARCTION	4 (4.7%)	[4]	2 (2.4%)	[4]	4 (4.8%)	[8]	0.682	>0.99
ATRIAL FIBRILLATION	1 (1.2%)	[1]	1 (1.2%)	[1]	3 (3.6%)	[5]	>0.99	0.365
ATRIAL FLUTTER	0		1 (1.2%)	[1]	1 (1.2%)	[2]	0.494	0.494
CARDIAC DISORDER	0		0		1 (1.2%)	[1]		0.494
SUPRAVENTRICULAR	1 (1.2%)	[2]	1 (1.2%)	[2]	1 (1.2%)	[1]	>0.99	>0.99
EXTRASYSTOLES								
VENTRICULAR EXTRASYSTOLES	0		2 (2.4%)	[4]	1 (1.2%)	[1]	0.243	0.494
ATRIAL HYPERTROPHY	1 (1.2%)	[2]	0		0		>0.99	>0.99
ATRIOVENTRICULAR BLOCK	1 (1.2%)	[1]	1 (1.2%)	[1]	0		>0.99	>0.99
FIRST DEGREE								
ATRIOVENTRICULAR BLOCK	1 (1.2%)	[1]	0		0		>0.99	>0.99
SECOND DEGREE								
BRADYCARDIA	1 (1.2%)	[4]	0		0		>0.99	>0.99
BUNDLE BRANCH BLOCK LEFT	1 (1.2%)	[1]	0		0		>0.99	>0.99
BUNDLE BRANCH BLOCK RIGHT	1 (1.2%)	[2]	1 (1.2%)	[1]	0		>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\atable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
CARDIAC FAILURE	1 (1.2%)	[1]	0		0		>0.99	>0.99
CONGESTIVE								
PALPITATIONS	0		2 (2.4%)	[2]	0		0.243	
SINUS ARRHYTHMIA	1 (1.2%)	[2]	0		0		>0.99	>0.99
SUPRAVENTRICULAR	0		1 (1.2%)	[2]	0		0.494	
TACHYCARDIA								
TACHYCARDIA	1 (1.2%)	[2]	0		0		>0.99	>0.99
VENTRICULAR HYPERTROPHY	1 (1.2%)	[1]	0		0		>0.99	>0.99
WOLFF-PARKINSON-WHITE	0		1 (1.2%)	[2]	0		0.494	
SYNDROME								
CONGENITAL, FAMILIAL AND	0		1 (1.2%)	[1]	2 (2.4%)	[2]	0.494	0.243
GENETIC DISORDE								
VENTRICULAR SEPTAL DEFECT	0		1 (1.2%)	[1]	2 (2.4%)	[2]	0.494	0.243
EAR AND LABYRINTH DISORDERS	1 (1.2%)	[2]	2 (2.4%)	[2]	1 (1.2%)	[1]	0.618	>0.99
VERTIGO	0		1 (1.2%)	[1]	1 (1.2%)	[1]	0.494	0.494
CERUMEN IMPACTION	0		1 (1.2%)	[1]	0		0.494	
EAR PAIN	1 (1.2%)	[2]	0		0		>0.99	>0.99
EYE DISORDERS	2 (2.3%)	[5]	2 (2.4%)	[2]	1 (1.2%)	[2]	>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]	Low Dose	High Dose
VISION BLURRED	0		1 (1.2%)	[1]	1 (1.2%)	[2]	0.494	0.494
CONJUNCTIVAL HAEMORRHAGE	0		1 (1.2%)	[1]	0		0.494	
CONJUNCTIVITIS	1 (1.2%)	[2]	0		0		>0.99	>0.99
EYE ALLERGY	1 (1.2%)	[1]	0		0		>0.99	>0.99
EYE PRURITUS	1 (1.2%)	[1]	0		0		>0.99	>0.99
EYE SWELLING	1 (1.2%)	[1]	0		0		>0.99	>0.99
GASTROINTESTINAL DISORDERS	17 (19.8%)	[26]	14 (16.7%)	[22]	20 (23.8%)	[36]	0.692	0.58
VOMITING	3 (3.5%)	[3]	3 (3.6%)	[4]	7 (8.3%)	[9]	>0.99	0.209
NAUSEA	3 (3.5%)	[3]	3 (3.6%)	[5]	6 (7.1%)	[13]	>0.99	0.326
DIARRHOEA	9 (10.5%)	[10]	4 (4.8%)	[5]	4 (4.8%)	[4]	0.248	0.248
SALIVARY HYPERSECRETION	0		0		4 (4.8%)	[5]		0.058*
ABDOMINAL DISCOMFORT	0		0		1 (1.2%)	[1]		0.494
ABDOMINAL PAIN	1 (1.2%)	[1]	3 (3.6%)	[3]	1 (1.2%)	[2]	0.365	>0.99
GASTROINTESTINAL HAEMORRHAGE	0		0		1 (1.2%)	[1]		0.494
STOMACH DISCOMFORT	0		0		1 (1.2%)	[1]		0.494
CONSTIPATION	1 (1.2%)	[1]	0		0		>0.99	>0.99
DYSPEPSIA	1 (1.2%)	[2]	1 (1.2%)	[2]	0		>0.99	>0.99
DYSPHAGIA	0		1 (1.2%)	[1]	0		0.494	
FLATULENCE	1 (1.2%)	[2]	0		0		>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
GASTROESOPHAGEAL REFLUX DISEASE	1 (1.2%)	[1]	0		0		>0.99	>0.99
GLOSSITIS	1 (1.2%)	[1]	0		0		>0.99	>0.99
HIATUS HERNIA	1 (1.2%)	[2]	0		0		>0.99	>0.99
RECTAL HAEMORRHAGE	0		1 (1.2%)	[2]	0		0.494	
GENERAL DISORDERS AND ADMINISTRATION SIT	21 (24.4%)	[46]	47 (56.0%)	[118]	40 (47.6%)	[124]	0.000*	0.002*
APPLICATION SITE PRURITUS	6 (7.0%)	[10]	22 (26.2%)	[32]	22 (26.2%)	[35]	0.001*	0.001*
APPLICATION SITE ERYTHEMA	3 (3.5%)	[3]	12 (14.3%)	[20]	15 (17.9%)	[23]	0.015*	0.003*
APPLICATION SITE IRRITATION	3 (3.5%)	[7]	9 (10.7%)	[18]	9 (10.7%)	[16]	0.078*	0.078*
APPLICATION SITE DERMATITIS	5 (5.8%)	[9]	9 (10.7%)	[15]	7 (8.3%)	[12]	0.277	0.563
APPLICATION SITE VESICLES	1 (1.2%)	[2]	4 (4.8%)	[5]	6 (7.1%)	[6]	0.208	0.062*
FATIGUE	1 (1.2%)	[2]	5 (6.0%)	[5]	5 (6.0%)	[5]	0.115*	0.115*
APPLICATION SITE PAIN	0		0		2 (2.4%)	[2]		0.243
APPLICATION SITE PERSPIRATION	0		0		2 (2.4%)	[3]		0.243
APPLICATION SITE SWELLING	0		1 (1.2%)	[1]	2 (2.4%)	[3]	0.494	0.243
CHEST DISCOMFORT	0		0		2 (2.4%)	[2]		0.243

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
CHEST PAIN	0		0		2 (2.4%)	[2]		0.243
MALAISE	0		1 (1.2%)	[2]	2 (2.4%)	[3]	0.494	0.243
OEDEMA PERIPHERAL	2 (2.3%)	[3]	1 (1.2%)	[1]	2 (2.4%)	[3]	>0.99	>0.99
APPLICATION SITE	0		0		1 (1.2%)	[1]		0.494
DISCHARGE								
APPLICATION SITE REACTION	1 (1.2%)	[2]	0		1 (1.2%)	[1]	>0.99	>0.99
APPLICATION SITE	0		2 (2.4%)	[2]	1 (1.2%)	[1]	0.243	0.494
URTICARIA								
ASTHENIA	1 (1.2%)	[2]	0		1 (1.2%)	[1]	>0.99	>0.99
CHILLS	1 (1.2%)	[3]	1 (1.2%)	[2]	1 (1.2%)	[1]	>0.99	>0.99
FEELING ABNORMAL	0		0		1 (1.2%)	[1]		0.494
FEELING COLD	0		0		1 (1.2%)	[1]		0.494
PAIN	0		1 (1.2%)	[2]	1 (1.2%)	[1]	0.494	0.494
PYREXIA	2 (2.3%)	[2]	0		1 (1.2%)	[1]	0.497	>0.99
APPLICATION SITE BLEEDING	0		1 (1.2%)	[1]	0		0.494	
APPLICATION SITE	0		1 (1.2%)	[1]	0		0.494	
DESQUAMATION								
APPLICATION SITE	0		1 (1.2%)	[1]	0		0.494	
DISCOLOURATION								
APPLICATION SITE	1 (1.2%)	[1]	0		0		>0.99	>0.99
INDURATION								

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
APPLICATION SITE WARMTH	0		1 (1.2%)	[2]	0		0.494	
INFLAMMATION	0		1 (1.2%)	[1]	0		0.494	
OEDEMA	0		2 (2.4%)	[2]	0		0.243	
SECRETION DISCHARGE	0		1 (1.2%)	[2]	0		0.494	
SUDDEN DEATH	0		1 (1.2%)	[1]	0		0.494	
SWELLING	0		1 (1.2%)	[1]	0		0.494	
ULCER	0		1 (1.2%)	[1]	0		0.494	
HEPATOBIILIARY DISORDERS	1 (1.2%)	[1]	0		0		>0.99	>0.99
HYPERBILIRUBINAEMIA	1 (1.2%)	[1]	0		0		>0.99	>0.99
IMMUNE SYSTEM DISORDERS	0		1 (1.2%)	[2]	0		0.494	
HYPERSENSITIVITY	0		1 (1.2%)	[2]	0		0.494	
INFECTIONS AND INFESTATIONS	16 (18.6%)	[35]	9 (10.7%)	[16]	13 (15.5%)	[20]	0.194	0.685
NASOPHARYNGITIS	2 (2.3%)	[4]	4 (4.8%)	[9]	6 (7.1%)	[8]	0.441	0.166
UPPER RESPIRATORY TRACT INFECTION	6 (7.0%)	[12]	1 (1.2%)	[2]	3 (3.6%)	[5]	0.117*	0.496
CYSTITIS	1 (1.2%)	[1]	0		1 (1.2%)	[1]	>0.99	>0.99
HORDEOLUM	0		0		1 (1.2%)	[1]		0.494
INFLUENZA	1 (1.2%)	[2]	1 (1.2%)	[1]	1 (1.2%)	[1]	>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Low Dose vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
LOWER RESPIRATORY TRACT INFECTION	0		0		1 (1.2%)	[2]		0.494
RHINITIS	0		0		1 (1.2%)	[1]		0.494
URINARY TRACT INFECTION	2 (2.3%)	[4]	0		1 (1.2%)	[1]	0.497	>0.99
BRONCHITIS	1 (1.2%)	[1]	0		0		>0.99	>0.99
CELLULITIS	0		1 (1.2%)	[1]	0		0.494	
CERVICITIS	1 (1.2%)	[2]	0		0		>0.99	>0.99
EAR INFECTION	2 (2.3%)	[4]	0		0		0.497	0.497
GASTROENTERITIS VIRAL	1 (1.2%)	[1]	0		0		>0.99	>0.99
LOCALISED INFECTION	1 (1.2%)	[2]	0		0		>0.99	>0.99
PNEUMONIA	0		1 (1.2%)	[2]	0		0.494	
VAGINAL MYCOSIS	1 (1.2%)	[2]	0		0		>0.99	>0.99
VIRAL INFECTION	0		1 (1.2%)	[1]	0		0.494	
INJURY, POISONING AND PROCEDURAL COMPLIC	4 (4.7%)	[9]	5 (6.0%)	[12]	5 (6.0%)	[8]	0.745	0.745
CONTUSION	1 (1.2%)	[1]	1 (1.2%)	[3]	2 (2.4%)	[3]	>0.99	0.618
HIP FRACTURE	1 (1.2%)	[2]	0		2 (2.4%)	[2]	>0.99	0.618
EXCORIATION	2 (2.3%)	[3]	1 (1.2%)	[2]	1 (1.2%)	[1]	>0.99	>0.99
FACIAL BONES FRACTURE	0		0		1 (1.2%)	[1]		0.494
FALL	1 (1.2%)	[2]	2 (2.4%)	[2]	1 (1.2%)	[1]	0.618	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\atable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
JOINT DISLOCATION	0		1 (1.2%)	[1]	0		0.494	
SKIN LACERATION	1 (1.2%)	[1]	2 (2.4%)	[2]	0		0.618	>0.99
WOUND	0		1 (1.2%)	[2]	0		0.494	
INVESTIGATIONS	10 (11.6%)	[19]	6 (7.1%)	[7]	6 (7.1%)	[8]	0.432	0.432
BIOPSY	0		0		1 (1.2%)	[1]		0.494
BIOPSY PROSTATE	0		0		1 (1.2%)	[1]		0.494
BLOOD CHOLESTEROL	0		0		1 (1.2%)	[1]		0.494
INCREASED								
BLOOD GLUCOSE INCREASED	0		1 (1.2%)	[1]	1 (1.2%)	[2]	0.494	0.494
ELECTROCARDIOGRAM T WAVE	2 (2.3%)	[3]	1 (1.2%)	[1]	1 (1.2%)	[1]	>0.99	>0.99
INVERSION								
WEIGHT DECREASED	0		0		1 (1.2%)	[2]		0.494
BLOOD ALKALINE	1 (1.2%)	[1]	0		0		>0.99	>0.99
PHOSPHATASE INCREASED								
BLOOD CREATINE	1 (1.2%)	[2]	0		0		>0.99	>0.99
PHOSPHOKINASE INCREASED								
BLOOD URINE PRESENT	1 (1.2%)	[1]	0		0		>0.99	>0.99
BODY TEMPERATURE	0		1 (1.2%)	[1]	0		0.494	
INCREASED								
CYSTOSCOPY	1 (1.2%)	[1]	0		0		>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]	Low Dose	High Dose
ELECTROCARDIOGRAM ST SEGMENT DEPRESSIO	4 (4.7%)	[4]	1 (1.2%)	[2]	0		0.368	0.121*
ELECTROCARDIOGRAM T WAVE AMPLITUDE DEC	1 (1.2%)	[1]	1 (1.2%)	[1]	0		>0.99	>0.99
HEART RATE INCREASED	1 (1.2%)	[2]	0		0		>0.99	>0.99
HEART RATE IRREGULAR	1 (1.2%)	[4]	0		0		>0.99	>0.99
NASAL MUCOSA BIOPSY	0		1 (1.2%)	[1]	0		0.494	
METABOLISM AND NUTRITION DISORDERS	6 (7.0%)	[8]	1 (1.2%)	[1]	2 (2.4%)	[4]	0.117*	0.278
DECREASED APPETITE	1 (1.2%)	[2]	0		1 (1.2%)	[2]	>0.99	>0.99
INCREASED APPETITE	1 (1.2%)	[2]	0		1 (1.2%)	[2]	>0.99	>0.99
DEHYDRATION	1 (1.2%)	[1]	0		0		>0.99	>0.99
DIABETES MELLITUS	1 (1.2%)	[1]	0		0		>0.99	>0.99
FOOD CRAVING	1 (1.2%)	[1]	1 (1.2%)	[1]	0		>0.99	>0.99
HYPONATRAEMIA	1 (1.2%)	[1]	0		0		>0.99	>0.99
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI	4 (4.7%)	[6]	7 (8.3%)	[10]	7 (8.3%)	[10]	0.367	0.367
BACK PAIN	1 (1.2%)	[2]	1 (1.2%)	[1]	3 (3.6%)	[4]	>0.99	0.365
ARTHRALGIA	1 (1.2%)	[1]	2 (2.4%)	[4]	1 (1.2%)	[1]	0.618	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
ARTHRITIS	0		0		1 (1.2%)	[1]		0.494
FLANK PAIN	0		0		1 (1.2%)	[1]		0.494
MUSCLE SPASMS	0		1 (1.2%)	[1]	1 (1.2%)	[2]	0.494	0.494
MYALGIA	0		0		1 (1.2%)	[1]		0.494
MUSCULAR WEAKNESS	0		1 (1.2%)	[2]	0		0.494	
PAIN IN EXTREMITY	1 (1.2%)	[1]	0		0		>0.99	>0.99
SHOULDER PAIN	1 (1.2%)	[2]	2 (2.4%)	[2]	0		0.618	>0.99
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIF	0		2 (2.4%)	[3]	1 (1.2%)	[1]	0.243	0.494
PROSTATE CANCER	0		0		1 (1.2%)	[1]		0.494
COLON CANCER	0		1 (1.2%)	[1]	0		0.494	
MALIGNANT FIBROUS HISTIOCYTOMA	0		1 (1.2%)	[2]	0		0.494	
NERVOUS SYSTEM DISORDERS	8 (9.3%)	[11]	20 (23.8%)	[40]	25 (29.8%)	[41]	0.013*	0.001*
DIZZINESS	2 (2.3%)	[3]	8 (9.5%)	[13]	11 (13.1%)	[15]	0.056*	0.009*
HEADACHE	3 (3.5%)	[3]	3 (3.6%)	[4]	5 (6.0%)	[8]	>0.99	0.493
SYNCOPE	0		4 (4.8%)	[6]	3 (3.6%)	[4]	0.058*	0.118*
BURNING SENSATION	0		0		2 (2.4%)	[2]		0.243
AMNESIA	0		0		1 (1.2%)	[2]		0.494

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Low Dose vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
COGNITIVE DISORDER	0		0		1 (1.2%)	[1]		0.494
HYPERSOMNIA	0		0		1 (1.2%)	[1]		0.494
LETHARGY	0		1 (1.2%)	[1]	1 (1.2%)	[1]	0.494	0.494
PARAESTHESIA	0		0		1 (1.2%)	[1]		0.494
PAROSMIA	0		0		1 (1.2%)	[2]		0.494
PARTIAL SEIZURES WITH SECONDARY GENERA	0		0		1 (1.2%)	[1]		0.494
SOMNOLENCE	2 (2.3%)	[3]	3 (3.6%)	[5]	1 (1.2%)	[1]	0.68	>0.99
SYNCOPE VASOVAGAL	0		0		1 (1.2%)	[1]		0.494
TRANSIENT ISCHAEMIC ATTACK	0		2 (2.4%)	[3]	1 (1.2%)	[1]	0.243	0.494
BALANCE DISORDER	0		1 (1.2%)	[3]	0		0.494	
COMPLEX PARTIAL SEIZURES	0		1 (1.2%)	[1]	0		0.494	
COORDINATION ABNORMAL	0		1 (1.2%)	[1]	0		0.494	
HEMIANOPIA HOMONYMOUS	0		1 (1.2%)	[1]	0		0.494	
PARAESTHESIA ORAL	0		1 (1.2%)	[1]	0		0.494	
PARKINSON'S DISEASE	1 (1.2%)	[1]	0		0		>0.99	>0.99
PSYCHOMOTOR HYPERACTIVITY	1 (1.2%)	[1]	0		0		>0.99	>0.99
STUPOR	0		1 (1.2%)	[1]	0		0.494	
PSYCHIATRIC DISORDERS	10 (11.6%)	[12]	10 (11.9%)	[14]	8 (9.5%)	[11]	>0.99	0.804

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\atable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]	Low Dose	High Dose
INSOMNIA	2 (2.3%)	[3]	0		2 (2.4%)	[2]	0.497	>0.99
AGITATION	2 (2.3%)	[2]	2 (2.4%)	[2]	1 (1.2%)	[1]	>0.99	>0.99
CONFUSIONAL STATE	2 (2.3%)	[2]	3 (3.6%)	[3]	1 (1.2%)	[1]	0.68	>0.99
DELIRIUM	0		0		1 (1.2%)	[1]		0.494
DELUSION	1 (1.2%)	[1]	0		1 (1.2%)	[1]	>0.99	>0.99
HALLUCINATION	0		0		1 (1.2%)	[1]		0.494
HALLUCINATION, VISUAL	0		0		1 (1.2%)	[1]		0.494
LIBIDO DECREASED	0		0		1 (1.2%)	[1]		0.494
LISTLESS	0		0		1 (1.2%)	[1]		0.494
NIGHTMARE	0		0		1 (1.2%)	[1]		0.494
ANXIETY	0		3 (3.6%)	[4]	0		0.118*	
COMPLETED SUICIDE	1 (1.2%)	[1]	0		0		>0.99	>0.99
DEPRESSED MOOD	0		1 (1.2%)	[2]	0		0.494	
DISORIENTATION	1 (1.2%)	[1]	0		0		>0.99	>0.99
IRRITABILITY	1 (1.2%)	[2]	1 (1.2%)	[1]	0		>0.99	>0.99
RESTLESSNESS	0		1 (1.2%)	[2]	0		0.494	
RENAL AND URINARY DISORDERS	4 (4.7%)	[5]	3 (3.6%)	[3]	3 (3.6%)	[4]	>0.99	>0.99
CALCULUS URETHRAL	0		0		1 (1.2%)	[1]		0.494
MICTURITION URGENCY	1 (1.2%)	[1]	1 (1.2%)	[1]	1 (1.2%)	[2]	>0.99	>0.99
NEPHROLITHIASIS	1 (1.2%)	[1]	0		1 (1.2%)	[1]	>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
DYSURIA	1 (1.2%)	[1]	1 (1.2%)	[1]	0		>0.99	>0.99
INCONTINENCE	0		1 (1.2%)	[1]	0		0.494	
POLLAKEIURIA	1 (1.2%)	[2]	0		0		>0.99	>0.99
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2 (2.3%)	[4]	0		1 (1.2%)	[1]	0.497	>0.99
BENIGN PROSTATIC HYPERPLASIA	1 (1.2%)	[2]	0		1 (1.2%)	[1]	>0.99	>0.99
PELVIC PAIN	1 (1.2%)	[2]	0		0		>0.99	>0.99
RESPIRATORY, THORACIC AND MEDIASTINAL DI	8 (9.3%)	[12]	9 (10.7%)	[14]	10 (11.9%)	[22]	0.803	0.626
COUGH	1 (1.2%)	[1]	5 (6.0%)	[7]	5 (6.0%)	[7]	0.115*	0.115*
NASAL CONGESTION	3 (3.5%)	[3]	1 (1.2%)	[1]	3 (3.6%)	[4]	0.621	>0.99
EPISTAXIS	0		1 (1.2%)	[1]	2 (2.4%)	[2]	0.494	0.243
ALLERGIC GRANULOMATOUS ANGIITIS	0		0		1 (1.2%)	[1]		0.494
DYSPNOEA	1 (1.2%)	[1]	1 (1.2%)	[1]	1 (1.2%)	[1]	>0.99	>0.99
PHARYNGEAL ERYTHEMA	0		0		1 (1.2%)	[2]		0.494
PHARYNGOLARYNGEAL PAIN	0		1 (1.2%)	[1]	1 (1.2%)	[1]	0.494	0.494
PRODUCTIVE COUGH	0		0		1 (1.2%)	[1]		0.494

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\atable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Low Dose vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
RESPIRATORY TRACT CONGESTION	0		0		1 (1.2%)	[1]		0.494
RHINORRHOEA	0		1 (1.2%)	[2]	1 (1.2%)	[2]	0.494	0.494
DYSPHONIA	0		1 (1.2%)	[1]	0		0.494	
EMPHYSEMA	1 (1.2%)	[1]	0		0		>0.99	>0.99
HAEMOPTYSIS	1 (1.2%)	[2]	0		0		>0.99	>0.99
POSTNASAL DRIP	1 (1.2%)	[2]	0		0		>0.99	>0.99
RALES	1 (1.2%)	[2]	0		0		>0.99	>0.99
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	20 (23.3%)	[45]	39 (46.4%)	[111]	40 (47.6%)	[104]	0.002*	0.001*
PRURITUS	8 (9.3%)	[11]	21 (25.0%)	[31]	26 (31.0%)	[38]	0.008*	0.000*
ERYTHEMA	8 (9.3%)	[12]	14 (16.7%)	[22]	14 (16.7%)	[22]	0.175	0.175
RASH	5 (5.8%)	[9]	13 (15.5%)	[18]	9 (10.7%)	[15]	0.048*	0.277
HYPERHIDROSIS	2 (2.3%)	[2]	4 (4.8%)	[5]	8 (9.5%)	[10]	0.441	0.056*
SKIN IRRITATION	3 (3.5%)	[4]	6 (7.1%)	[13]	5 (6.0%)	[8]	0.326	0.493
RASH PRURITIC	0		1 (1.2%)	[2]	2 (2.4%)	[3]	0.494	0.243
ACTINIC KERATOSIS	0		0		1 (1.2%)	[1]		0.494
BLISTER	0		5 (6.0%)	[8]	1 (1.2%)	[2]	0.028*	0.494
PRURITUS GENERALISED	0		1 (1.2%)	[4]	1 (1.2%)	[1]	0.494	0.494
RASH MACULO-PAPULAR	0		0		1 (1.2%)	[1]		0.494

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. Low Dose High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
SKIN ODOUR ABNORMAL	0		0		1 (1.2%)	[1]		0.494
URTICARIA	0		1 (1.2%)	[3]	1 (1.2%)	[2]	0.494	0.494
ALOPECIA	1 (1.2%)	[1]	0		0		>0.99	>0.99
COLD SWEAT	1 (1.2%)	[3]	0		0		>0.99	>0.99
DERMATITIS CONTACT	0		1 (1.2%)	[2]	0		0.494	
DRUG ERUPTION	1 (1.2%)	[1]	0		0		>0.99	>0.99
RASH ERYTHEMATOUS	0		1 (1.2%)	[1]	0		0.494	
SKIN EXFOLIATION	0		1 (1.2%)	[2]	0		0.494	
SKIN ULCER	1 (1.2%)	[2]	0		0		>0.99	>0.99
SOCIAL CIRCUMSTANCES	0		0		1 (1.2%)	[1]		0.494
ALCOHOL USE	0		0		1 (1.2%)	[1]		0.494
SURGICAL AND MEDICAL PROCEDURES	2 (2.3%)	[2]	1 (1.2%)	[1]	2 (2.4%)	[2]	>0.99	>0.99
ACROCHORDON EXCISION	0		0		1 (1.2%)	[1]		0.494
SKIN LESION EXCISION	0		0		1 (1.2%)	[1]		0.494
CATARACT OPERATION	1 (1.2%)	[1]	1 (1.2%)	[1]	0		>0.99	>0.99
EYE LASER SURGERY	1 (1.2%)	[1]	0		0		>0.99	>0.99
VASCULAR DISORDERS	3 (3.5%)	[7]	3 (3.6%)	[3]	1 (1.2%)	[1]	>0.99	0.621

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Protocol: CDISCILOT01

Page 16 of 16

Population: Safety

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]	Low Dose	High Dose
WOUND HAEMORRHAGE	0		0		1 (1.2%)	[1]	0.494	0.494
HOT FLUSH	0		1 (1.2%)	[1]	0		0.494	
HYPERTENSION	1 (1.2%)	[2]	1 (1.2%)	[1]	0		>0.99	>0.99
HYPOTENSION	2 (2.3%)	[3]	1 (1.2%)	[1]	0		>0.99	0.497
ORTHOSTATIC HYPOTENSION	1 (1.2%)	[2]	0		0		>0.99	>0.99

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\aetable.sas

21:41 Monday, June 26, 2006

Table 14-5.02

Incidence of Treatment Emergent Serious Adverse Events by Treatment Group

System Organ Class/ Preferred Term	Placebo (N=86)		Xanomeline Low (N=84)		Xanomeline High (N=84)		Fisher's Exact p-values Placebo vs. Low Dose vs. Placebo vs. High Dose	
	n(%)	[AEs]	n(%)	[AEs]	n(%)	[AEs]		
ANY BODY SYSTEM	0		1 (1.2%)	[1]	2 (2.4%)	[2]	0.494	0.243
NERVOUS SYSTEM DISORDERS	0		1 (1.2%)	[1]	2 (2.4%)	[2]	0.494	0.243
SYNCOPE	0		1 (1.2%)	[1]	1 (1.2%)	[1]	0.494	0.494
PARTIAL SEIZURES WITH SECONDARY GENERA	0		0		1 (1.2%)	[1]		0.494

Note: Treatment emergent events are defined as events which start on or after the start of treatment.

Note: Adverse events are coded using MedDRA.

Note: Percentages are based on the number of subjects in the safety population within each treatment group.

Note: P-values are based on Fisher's Exact test for the comparison of placebo versus each active treatment group. An asterisk is appended to p-values that are less than 0.15.

Note: The column [AE] represents the total number of times an event was recorded.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\saetable.sas

21:44 Monday, June 26, 2006

Protocol: CDISCPilot01

Page 1 of 15

Population: Safety

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High			
Visit	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)		
CHEMISTRY											
ALANINE AMINOTRANSFERASE											
Bsln	86	17.6 (9.22)		82	18.0 (8.72)		84	19.2 (10.05)			
Wk 2	83	18.0 (12.53)	0.2 (7.90)	80	20.9 (10.55)	2.8 (8.18)	78	21.0 (8.87)	1.6 (6.83)		
Wk 4	79	18.7 (12.91)	0.7 (8.66)	72	17.5 (7.66)	-0.7 (5.08)	72	21.3 (9.51)	2.1 (7.08)		
Wk 6	73	17.0 (9.92)	-0.3 (7.78)	62	17.0 (7.98)	-0.8 (4.87)	66	21.2 (9.49)	1.6 (6.11)		
Wk 8	72	16.7 (9.34)	-1.1 (5.05)	60	17.6 (7.86)	0.2 (5.45)	56	22.8 (17.49)	3.2 (17.24)		
Wk 12	67	18.0 (9.16)	0.0 (8.07)	51	18.5 (12.68)	0.1 (9.27)	50	21.0 (10.18)	0.7 (8.74)		
Wk 16	68	17.1 (7.39)	-0.8 (7.94)	42	17.3 (7.51)	0.7 (5.80)	37	19.6 (7.61)	-0.3 (7.58)		
Wk 20	65	16.1 (6.56)	-1.9 (7.49)	30	16.7 (6.33)	0.9 (4.77)	31	19.6 (6.82)	-0.3 (8.63)		
Wk 24	57	17.9 (15.61)	-0.3 (16.62)	26	18.2 (9.17)	1.6 (5.66)	30	21.0 (8.70)	0.2 (8.25)		
Wk 26	57	16.0 (5.98)	-2.1 (7.70)	25	17.8 (9.51)	1.5 (6.26)	27	18.9 (7.02)	-2.0 (7.01)		
End[1]	84	18.1 (16.74)	0.4 (15.40)	82	18.3 (8.26)	0.3 (7.25)	80	19.5 (7.44)	0.1 (8.08)		
ALBUMIN											
Bsln	86	39.8 (2.81)		82	39.8 (2.56)		84	40.3 (2.84)			
Wk 2	83	38.9 (3.11)	-1.0 (2.49)	80	38.7 (3.17)	-1.1 (2.71)	78	38.9 (2.76)	-1.4 (2.59)		
Wk 4	79	38.8 (3.29)	-1.0 (2.69)	72	38.6 (2.80)	-1.2 (2.66)	72	39.1 (3.05)	-1.3 (2.70)		
Wk 6	73	39.1 (2.56)	-1.0 (2.25)	62	38.4 (2.60)	-1.2 (2.49)	66	39.5 (2.76)	-1.0 (2.60)		
Wk 8	72	39.8 (3.51)	-0.4 (2.70)	60	39.1 (2.93)	-0.5 (2.73)	56	39.8 (2.33)	-0.9 (2.21)		
Wk 12	67	39.5 (3.49)	-0.5 (2.31)	51	38.9 (2.18)	-0.9 (2.19)	50	39.8 (2.45)	-0.6 (2.77)		
Wk 16	68	40.4 (3.02)	0.4 (2.45)	42	39.1 (2.98)	-0.4 (2.78)	37	39.9 (1.92)	-0.7 (2.76)		
Wk 20	65	39.6 (3.47)	-0.5 (2.86)	30	38.6 (2.66)	-1.2 (2.55)	31	39.6 (1.85)	-1.4 (2.86)		
Wk 24	57	39.7 (3.34)	-0.2 (2.88)	26	40.4 (2.52)	0.4 (2.40)	30	40.5 (2.10)	-0.5 (2.65)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High			
			Change from Bsln			Change from Bsln			Change from Bsln		
Visit	N	Mean (SD)	Mean (SD)	N	Mean (SD)	Mean (SD)	N	Mean (SD)	Mean (SD)	N	Mean (SD)
Wk 26	57	39.8 (3.02)	0.0 (2.26)	25	39.2 (2.39)	-1.0 (2.85)	27	40.0 (2.26)	-1.2 (2.78)		
End[1]	84	39.6 (3.32)	-0.2 (2.69)	82	39.2 (2.97)	-0.5 (2.64)	80	39.8 (2.48)	-0.6 (2.64)		
ALKALINE PHOSPHATASE											
Bsln	86	77.7 (58.11)		81	73.3 (20.72)		83	71.0 (38.85)			
Wk 2	84	77.7 (69.50)	0.1 (15.51)	80	73.0 (21.87)	0.3 (10.25)	78	72.2 (40.22)	-0.1 (8.09)		
Wk 4	82	78.0 (69.43)	0.4 (14.16)	72	73.2 (23.17)	-0.3 (11.12)	72	71.3 (40.65)	-0.7 (6.88)		
Wk 6	75	68.4 (21.53)	-0.4 (10.40)	64	72.7 (23.15)	-1.0 (10.83)	67	71.5 (43.40)	-0.2 (12.65)		
Wk 8	73	70.0 (27.15)	-0.0 (10.67)	60	72.9 (23.84)	0.5 (14.09)	56	74.0 (45.60)	0.8 (13.54)		
Wk 12	67	72.1 (32.73)	1.8 (17.18)	52	69.5 (20.55)	-1.5 (9.41)	50	71.9 (46.65)	-1.7 (8.53)		
Wk 16	68	70.6 (29.49)	0.3 (16.98)	42	69.5 (19.43)	-1.7 (8.61)	37	74.7 (54.78)	-1.4 (8.29)		
Wk 20	65	72.6 (37.41)	1.9 (25.77)	31	70.6 (22.20)	-2.2 (9.90)	31	73.5 (55.23)	-2.7 (8.35)		
Wk 24	56	80.6 (68.06)	10.1 (58.71)	27	72.0 (21.80)	-0.4 (8.93)	30	64.4 (17.63)	-2.4 (7.44)		
Wk 26	57	81.0 (79.33)	10.1 (72.41)	25	68.6 (21.08)	-4.1 (10.74)	27	61.9 (16.60)	-3.9 (7.65)		
End[1]	84	84.6 (84.86)	7.1 (49.37)	82	71.6 (23.80)	-1.1 (13.09)	80	70.3 (37.91)	-1.6 (12.00)		
ASPARTATE AMINOTRANSFERASE											
Bsln	86	23.2 (7.50)		82	23.4 (8.24)		84	23.1 (6.61)			
Wk 2	83	23.6 (12.35)	0.2 (8.96)	80	24.7 (8.06)	1.6 (6.53)	78	23.4 (5.20)	0.4 (5.63)		
Wk 4	79	23.9 (14.93)	0.5 (11.33)	72	22.3 (6.75)	-1.4 (6.40)	72	23.8 (5.85)	0.6 (5.75)		
Wk 6	73	22.0 (6.40)	-0.9 (6.38)	62	22.1 (6.11)	-0.4 (4.19)	66	24.1 (7.84)	0.4 (6.10)		
Wk 8	72	22.3 (7.05)	-1.1 (4.84)	60	22.7 (5.95)	0.3 (4.02)	56	25.7 (13.33)	1.6 (13.98)		
Wk 12	67	22.8 (7.64)	-0.6 (7.06)	51	24.2 (15.87)	1.5 (12.39)	50	23.3 (6.11)	-1.2 (6.26)		
Wk 16	68	22.8 (6.42)	-0.6 (6.43)	42	22.4 (10.34)	0.6 (7.62)	37	23.1 (5.78)	-0.7 (4.17)		
Wk 20	65	21.9 (5.90)	-1.6 (6.07)	30	20.7 (5.74)	0.4 (4.60)	31	24.0 (6.90)	-0.3 (6.18)		
Wk 24	57	25.2 (21.02)	1.2 (20.43)	26	22.4 (10.78)	2.1 (6.58)	30	24.4 (7.29)	-0.2 (5.48)		
Wk 26	57	21.5 (6.99)	-2.5 (7.29)	25	22.1 (11.85)	1.4 (7.69)	27	21.6 (5.71)	-3.1 (4.17)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High				
				Change from Bsln				Change from Bsln				Change from Bsln
Visit	N	Mean (SD)	Mean (SD)	N	Mean (SD)	Mean (SD)	N	Mean (SD)	Mean (SD)	N	Mean (SD)	Mean (SD)
End[1]	84	25.1 (21.33)	1.8 (19.03)	82	23.2 (8.21)	-0.3 (8.06)	80	22.7 (6.13)	-0.4 (6.36)			
BILIRUBIN												
Bsln	86	9.7 (3.96)		82	9.4 (4.01)		84	11.0 (5.35)				
Wk 2	83	10.8 (12.26)	1.1 (10.29)	79	9.4 (4.16)	-0.0 (3.08)	78	10.4 (3.94)	-0.6 (3.62)			
Wk 4	79	11.1 (13.57)	1.4 (11.65)	71	9.2 (3.84)	-0.3 (2.70)	72	10.9 (5.62)	-0.3 (3.07)			
Wk 6	73	9.6 (3.78)	0.1 (2.88)	62	9.5 (4.03)	-0.0 (2.99)	66	10.9 (4.89)	-0.6 (3.18)			
Wk 8	72	9.4 (3.89)	-0.4 (3.43)	60	9.6 (4.72)	0.5 (3.11)	56	10.8 (5.21)	-0.7 (3.21)			
Wk 12	67	9.5 (3.56)	-0.1 (2.83)	51	8.8 (4.15)	0.1 (2.64)	50	11.5 (6.16)	-0.3 (4.78)			
Wk 16	68	10.0 (3.63)	0.2 (2.68)	42	8.8 (3.91)	0.4 (2.14)	37	11.6 (4.89)	-0.7 (4.28)			
Wk 20	65	10.1 (5.19)	0.3 (3.58)	30	8.8 (4.51)	0.3 (2.82)	31	11.8 (8.69)	-0.2 (6.41)			
Wk 24	55	9.4 (3.39)	0.1 (2.75)	25	10.1 (4.44)	1.1 (2.84)	30	12.3 (6.52)	-0.6 (2.89)			
Wk 26	57	10.0 (4.73)	0.4 (3.57)	25	10.2 (6.21)	1.4 (3.44)	27	12.2 (6.82)	-0.6 (5.31)			
End[1]	82	11.2 (13.42)	1.4 (11.28)	80	9.8 (4.29)	0.5 (3.08)	80	11.1 (5.36)	-0.0 (3.16)			
CALCIUM												
Bsln	86	2.3 (0.09)		82	2.3 (0.11)		84	2.3 (0.10)				
Wk 2	84	2.3 (0.09)	-0.0 (0.10)	80	2.3 (0.12)	-0.0 (0.10)	78	2.3 (0.11)	-0.0 (0.11)			
Wk 4	82	2.3 (0.09)	-0.0 (0.09)	72	2.3 (0.10)	-0.0 (0.08)	72	2.3 (0.10)	-0.0 (0.10)			
Wk 6	75	2.3 (0.09)	-0.0 (0.10)	64	2.3 (0.10)	-0.0 (0.08)	67	2.3 (0.09)	-0.0 (0.10)			
Wk 8	73	2.3 (0.09)	-0.0 (0.09)	60	2.3 (0.12)	-0.0 (0.09)	56	2.3 (0.12)	-0.0 (0.11)			
Wk 12	67	2.3 (0.09)	-0.0 (0.08)	52	2.3 (0.10)	-0.0 (0.07)	50	2.3 (0.09)	-0.0 (0.09)			
Wk 16	68	2.3 (0.10)	-0.0 (0.11)	42	2.3 (0.11)	-0.0 (0.08)	37	2.3 (0.11)	-0.0 (0.12)			
Wk 20	66	2.3 (0.09)	-0.0 (0.09)	31	2.3 (0.10)	-0.0 (0.09)	31	2.3 (0.08)	-0.0 (0.09)			
Wk 24	57	2.3 (0.09)	-0.1 (0.10)	27	2.3 (0.11)	-0.0 (0.12)	30	2.3 (0.10)	-0.1 (0.12)			
Wk 26	57	2.3 (0.10)	-0.0 (0.10)	25	2.3 (0.10)	-0.0 (0.08)	27	2.3 (0.09)	-0.0 (0.10)			
End[1]	84	2.3 (0.09)	-0.0 (0.10)	82	2.3 (0.10)	-0.0 (0.10)	80	2.3 (0.10)	-0.0 (0.11)			

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Visit	Placebo			Xanomeline Low			Xanomeline High		
	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)
CHLORIDE									
Bsln	86	105.7 (3.19)		82	105.8 (3.25)		83	105.4 (3.33)	
Wk 2	84	106.0 (3.12)	0.3 (3.40)	80	105.6 (3.12)	-0.0 (3.44)	77	104.4 (3.49)	-0.8 (3.88)
Wk 4	82	105.6 (3.53)	-0.1 (4.24)	72	105.5 (2.88)	-0.3 (3.72)	72	105.0 (3.46)	-0.4 (3.94)
Wk 6	75	105.5 (3.14)	-0.1 (3.61)	64	106.3 (3.07)	0.6 (3.78)	67	105.3 (3.09)	-0.3 (3.47)
Wk 8	73	106.0 (3.34)	0.3 (3.52)	60	105.6 (3.01)	-0.2 (3.47)	56	105.2 (3.57)	-0.1 (3.71)
Wk 12	67	105.3 (2.93)	-0.3 (3.75)	52	105.7 (3.21)	-0.4 (3.63)	49	105.2 (2.40)	-0.1 (2.64)
Wk 16	68	105.5 (3.16)	-0.0 (3.57)	42	106.2 (2.93)	0.2 (3.17)	37	105.9 (2.66)	0.6 (2.54)
Wk 20	65	106.0 (3.68)	0.6 (4.13)	31	106.3 (2.75)	-0.1 (2.41)	31	105.4 (3.03)	-0.2 (3.69)
Wk 24	57	105.5 (3.14)	-0.1 (3.82)	27	105.3 (2.52)	-1.2 (2.95)	30	105.3 (3.21)	-0.1 (3.06)
Wk 26	57	106.2 (2.58)	0.8 (3.33)	25	105.7 (2.35)	-0.5 (2.72)	27	105.7 (3.44)	0.4 (2.92)
End[1]	84	105.6 (3.42)	-0.1 (3.86)	82	105.5 (3.37)	-0.1 (3.31)	80	105.0 (3.20)	-0.5 (3.17)
CHOLESTEROL									
Bsln	86	5.8 (1.07)		82	5.7 (1.00)		84	5.8 (1.02)	
Wk 2	84	5.6 (1.02)	-0.1 (0.54)	80	5.6 (0.92)	-0.1 (0.50)	78	5.6 (0.93)	-0.2 (0.53)
Wk 4	82	5.5 (0.94)	-0.2 (0.57)	72	5.5 (0.97)	-0.2 (0.49)	72	5.5 (1.00)	-0.3 (0.51)
Wk 6	75	5.6 (0.95)	-0.1 (0.67)	64	5.4 (0.95)	-0.2 (0.55)	67	5.5 (0.91)	-0.3 (0.64)
Wk 8	73	5.5 (1.02)	-0.2 (0.71)	60	5.5 (0.96)	-0.2 (0.49)	56	5.5 (0.94)	-0.3 (0.54)
Wk 12	67	5.5 (0.92)	-0.2 (0.57)	52	5.3 (0.90)	-0.3 (0.47)	50	5.4 (0.91)	-0.3 (0.63)
Wk 16	68	5.6 (0.98)	-0.1 (0.58)	42	5.3 (1.00)	-0.3 (0.48)	37	5.4 (0.94)	-0.2 (0.55)
Wk 20	66	5.5 (0.94)	-0.2 (0.68)	31	5.2 (0.86)	-0.4 (0.46)	31	5.3 (0.85)	-0.3 (0.49)
Wk 24	57	5.5 (1.01)	-0.3 (0.68)	27	5.4 (0.94)	-0.2 (0.65)	30	5.3 (0.89)	-0.3 (0.50)
Wk 26	57	5.5 (0.94)	-0.3 (0.62)	25	5.2 (0.76)	-0.4 (0.64)	27	5.4 (0.90)	-0.2 (0.81)
End[1]	84	5.5 (1.02)	-0.3 (0.76)	82	5.4 (0.96)	-0.3 (0.56)	80	5.4 (0.89)	-0.4 (0.60)

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Visit	Placebo			Xanomeline Low			Xanomeline High		
	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)
CREATINE KINASE									
Bsln	86	86.9 (43.71)		82	100.6 (68.87)		84	104.0 (71.75)	
Wk 2	83	90.3 (66.11)	2.4 (57.72)	80	106.1 (83.92)	6.0 (84.97)	78	93.8 (53.19)	-12.0 (52.92)
Wk 4	79	96.9 (124.45)	8.3 (116.54)	72	93.2 (51.67)	-7.8 (55.54)	72	100.6 (58.39)	-4.8 (53.80)
Wk 6	73	88.0 (42.36)	-0.3 (40.55)	62	89.0 (44.29)	-13.7 (59.25)	66	123.5 (227.36)	17.8 (187.17)
Wk 8	72	93.8 (45.84)	1.2 (46.26)	60	90.0 (39.16)	-8.3 (61.09)	56	91.8 (52.25)	-9.3 (59.25)
Wk 12	67	101.8 (78.66)	8.9 (67.77)	51	94.7 (53.59)	-7.2 (65.59)	50	96.6 (60.55)	-2.8 (66.47)
Wk 16	68	104.9 (66.37)	12.7 (52.13)	42	97.5 (56.39)	-6.9 (72.02)	37	86.1 (47.70)	-1.6 (24.32)
Wk 20	65	93.8 (46.56)	1.0 (42.07)	30	111.6 (137.04)	21.5 (136.75)	31	97.5 (68.57)	6.0 (28.57)
Wk 24	57	127.4 (207.98)	32.6 (200.00)	26	83.6 (38.60)	0.8 (21.99)	30	90.9 (53.97)	-1.1 (23.40)
Wk 26	57	94.1 (51.03)	2.0 (46.93)	25	69.9 (23.70)	-15.0 (17.45)	27	93.0 (59.94)	1.4 (43.90)
End[1]	84	112.6 (173.34)	24.6 (165.91)	82	98.2 (61.12)	-1.9 (67.09)	80	95.1 (56.32)	-9.9 (60.94)
CREATININE									
Bsln	86	97.7 (17.78)		82	103.5 (20.01)		84	103.7 (19.37)	
Wk 2	84	99.0 (17.51)	1.4 (8.06)	80	106.2 (21.26)	2.3 (10.51)	78	106.3 (21.18)	2.8 (9.50)
Wk 4	82	98.6 (18.56)	1.1 (11.40)	72	105.1 (19.83)	2.0 (8.13)	72	105.8 (20.66)	2.6 (10.43)
Wk 6	75	101.7 (18.46)	3.3 (12.14)	64	104.4 (19.85)	1.7 (9.31)	67	105.8 (20.87)	3.2 (9.94)
Wk 8	73	99.1 (16.07)	-0.0 (9.88)	60	104.3 (21.27)	1.8 (7.54)	56	106.1 (22.24)	3.2 (9.14)
Wk 12	67	101.5 (16.53)	2.4 (9.68)	52	101.8 (17.72)	1.8 (7.99)	50	108.2 (20.48)	5.8 (10.95)
Wk 16	68	100.4 (16.43)	1.2 (10.57)	42	98.5 (16.63)	-1.3 (9.29)	37	102.5 (17.86)	2.2 (9.18)
Wk 20	66	100.3 (17.92)	1.3 (11.31)	31	97.2 (17.23)	-1.8 (8.17)	31	103.5 (19.66)	3.1 (11.76)
Wk 24	57	99.3 (15.85)	0.8 (11.37)	27	99.2 (16.14)	1.7 (7.08)	30	100.2 (19.61)	-0.6 (10.36)
Wk 26	57	100.0 (18.46)	2.0 (9.30)	25	99.7 (18.84)	2.9 (8.10)	27	101.8 (18.73)	0.3 (8.31)
End[1]	84	98.5 (16.13)	0.8 (10.77)	82	105.6 (19.79)	1.8 (8.60)	80	104.6 (20.50)	1.4 (10.38)

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low			Xanomeline High				
Visit	N	Mean (SD)	Change	N	Mean (SD)	Change	N	Mean (SD)	Change		
			from Bsln Mean (SD)			from Bsln Mean (SD)			from Bsln Mean (SD)		
GAMMA GLUTAMYL TRANSFERASE											
Bsln	86	24.9 (49.75)		82	22.2 (15.57)		84	22.8 (17.71)			
Wk 2	84	24.2 (47.03)	-0.8 (5.52)	80	22.6 (15.52)	0.2 (9.48)	78	23.7 (18.17)	0.6 (8.96)		
Wk 4	82	24.5 (48.68)	-0.8 (5.69)	72	21.8 (13.82)	-1.1 (7.51)	72	23.3 (16.08)	0.1 (9.29)		
Wk 6	75	19.9 (15.55)	0.3 (6.11)	64	21.9 (13.72)	-0.6 (6.88)	67	21.6 (13.48)	-0.5 (6.74)		
Wk 8	73	20.6 (16.38)	0.1 (6.76)	60	23.6 (15.55)	1.1 (11.36)	56	26.8 (29.96)	4.0 (24.63)		
Wk 12	67	21.4 (15.04)	0.5 (5.70)	52	21.9 (13.97)	-0.7 (8.80)	50	24.7 (21.26)	1.2 (8.19)		
Wk 16	68	20.8 (13.00)	-0.1 (5.65)	42	22.8 (14.86)	-0.1 (6.38)	37	23.9 (17.79)	-1.3 (6.16)		
Wk 20	66	20.4 (13.90)	-0.5 (5.42)	31	24.1 (17.52)	-0.4 (5.90)	31	22.2 (11.28)	-0.5 (5.98)		
Wk 24	57	22.0 (16.68)	0.5 (10.90)	27	23.7 (14.75)	0.5 (7.28)	30	25.5 (22.64)	-0.9 (6.48)		
Wk 26	57	21.4 (13.91)	-0.4 (7.08)	25	22.0 (15.31)	-1.0 (8.44)	27	23.4 (18.73)	-3.4 (7.97)		
End[1]	84	25.7 (48.78)	0.7 (9.60)	82	22.4 (14.03)	0.3 (10.36)	80	22.3 (15.66)	-0.6 (9.81)		
GLUCOSE											
Bsln	86	5.6 (2.14)		82	5.4 (0.94)		84	5.4 (1.34)			
Wk 2	83	5.6 (1.87)	-0.0 (1.37)	80	5.6 (1.75)	0.1 (1.50)	78	6.1 (2.92)	0.7 (2.06)		
Wk 4	79	5.6 (1.87)	-0.0 (1.55)	70	5.4 (1.41)	-0.1 (1.09)	72	5.9 (1.84)	0.4 (1.25)		
Wk 6	73	5.7 (2.22)	0.1 (1.37)	62	5.3 (1.34)	-0.1 (1.12)	66	6.0 (2.80)	0.5 (2.20)		
Wk 8	72	5.5 (1.35)	-0.1 (2.09)	59	5.5 (1.76)	0.1 (1.34)	56	5.8 (2.15)	0.2 (1.68)		
Wk 12	67	6.1 (1.97)	0.4 (1.97)	51	5.9 (3.18)	0.4 (2.78)	49	6.0 (2.28)	0.4 (1.64)		
Wk 16	68	5.5 (1.42)	-0.2 (1.69)	42	5.3 (0.83)	-0.2 (0.89)	37	5.9 (2.30)	0.2 (1.74)		
Wk 20	65	5.8 (1.50)	0.1 (2.08)	30	5.7 (1.73)	0.1 (1.39)	31	5.8 (1.61)	0.2 (1.47)		
Wk 24	57	5.7 (1.83)	-0.1 (2.68)	26	5.7 (1.26)	0.2 (0.82)	30	6.0 (1.92)	0.5 (1.94)		
Wk 26	57	5.8 (1.85)	-0.0 (1.60)	25	5.5 (1.72)	0.1 (1.35)	27	5.6 (1.01)	0.1 (1.66)		
End[1]	84	5.6 (1.61)	0.0 (2.26)	82	5.4 (1.07)	-0.1 (1.03)	80	5.9 (2.15)	0.5 (1.62)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High			
Visit	N	Mean (SD)	Change	N	Mean (SD)	Change	N	Mean (SD)	Change		
			from Bsln			from Bsln			from Bsln		
			Mean (SD)			Mean (SD)			Mean (SD)		
PHOSPHATE											
Bsln	86	1.2 (0.15)		81	1.2 (0.11)		83	1.2 (0.15)			
Wk 2	84	1.2 (0.15)	0.0 (0.16)	80	1.2 (0.15)	-0.0 (0.16)	78	1.2 (0.18)	0.0 (0.19)		
Wk 4	82	1.1 (0.16)	-0.0 (0.17)	71	1.1 (0.14)	-0.0 (0.14)	72	1.2 (0.18)	-0.0 (0.16)		
Wk 6	75	1.2 (0.15)	0.0 (0.17)	64	1.2 (0.17)	0.0 (0.17)	67	1.2 (0.15)	-0.0 (0.16)		
Wk 8	73	1.1 (0.14)	0.0 (0.13)	60	1.1 (0.16)	-0.0 (0.16)	56	1.2 (0.16)	-0.0 (0.18)		
Wk 12	67	1.2 (0.16)	0.0 (0.18)	52	1.1 (0.14)	-0.0 (0.18)	50	1.1 (0.15)	-0.0 (0.17)		
Wk 16	68	1.1 (0.14)	-0.0 (0.15)	42	1.1 (0.17)	-0.0 (0.19)	37	1.2 (0.17)	0.0 (0.17)		
Wk 20	65	1.2 (0.17)	0.0 (0.15)	31	1.1 (0.13)	0.0 (0.14)	31	1.2 (0.15)	-0.0 (0.16)		
Wk 24	56	1.2 (0.15)	0.0 (0.16)	27	1.2 (0.19)	0.1 (0.19)	30	1.1 (0.17)	-0.0 (0.17)		
Wk 26	57	1.2 (0.15)	0.0 (0.18)	25	1.1 (0.17)	0.0 (0.17)	27	1.2 (0.19)	0.0 (0.20)		
End[1]	84	1.2 (0.17)	0.0 (0.18)	82	1.2 (0.17)	0.0 (0.18)	80	1.2 (0.16)	0.0 (0.17)		
POTASSIUM											
Bsln	86	4.3 (0.43)		81	4.3 (0.34)		82	4.3 (0.41)			
Wk 2	84	4.2 (0.41)	-0.0 (0.37)	80	4.3 (0.41)	-0.0 (0.38)	77	4.3 (0.40)	-0.0 (0.46)		
Wk 4	82	4.2 (0.37)	-0.1 (0.38)	71	4.3 (0.40)	-0.1 (0.36)	72	4.2 (0.37)	-0.1 (0.46)		
Wk 6	75	4.3 (0.33)	0.0 (0.41)	64	4.3 (0.39)	-0.1 (0.41)	67	4.2 (0.32)	-0.1 (0.44)		
Wk 8	73	4.2 (0.37)	-0.1 (0.43)	60	4.3 (0.39)	-0.0 (0.38)	56	4.2 (0.39)	-0.0 (0.50)		
Wk 12	67	4.2 (0.41)	-0.0 (0.46)	52	4.2 (0.42)	-0.2 (0.40)	49	4.2 (0.26)	-0.1 (0.39)		
Wk 16	68	4.2 (0.41)	-0.0 (0.46)	42	4.3 (0.33)	-0.1 (0.35)	37	4.3 (0.27)	0.0 (0.35)		
Wk 20	64	4.3 (0.46)	0.0 (0.44)	31	4.3 (0.36)	-0.0 (0.44)	31	4.3 (0.37)	0.0 (0.40)		
Wk 24	56	4.3 (0.44)	0.1 (0.44)	27	4.3 (0.41)	-0.0 (0.35)	30	4.2 (0.42)	-0.0 (0.50)		
Wk 26	57	4.2 (0.38)	0.0 (0.34)	25	4.3 (0.40)	-0.0 (0.36)	27	4.3 (0.39)	0.0 (0.54)		
End[1]	84	4.3 (0.43)	0.0 (0.41)	82	4.3 (0.43)	-0.1 (0.39)	80	4.2 (0.36)	-0.1 (0.47)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Visit	Placebo			Xanomeline Low			Xanomeline High		
	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)
PROTEIN									
Bsln	86	70.5 (4.72)		82	70.4 (4.29)		84	71.0 (4.24)	
Wk 2	84	69.2 (4.93)	-1.3 (4.53)	80	69.5 (4.48)	-0.9 (3.63)	78	69.5 (4.31)	-1.6 (3.91)
Wk 4	82	69.0 (4.18)	-1.6 (3.93)	72	68.8 (4.30)	-1.5 (3.97)	72	69.8 (4.54)	-1.4 (3.90)
Wk 6	75	69.6 (3.95)	-1.2 (4.01)	64	68.8 (4.33)	-1.3 (4.17)	67	70.2 (4.28)	-1.1 (4.10)
Wk 8	73	70.5 (5.20)	-0.4 (4.35)	60	69.2 (3.95)	-0.9 (3.71)	56	70.6 (3.78)	-1.0 (3.57)
Wk 12	67	70.0 (4.28)	-0.6 (3.86)	52	69.3 (4.98)	-0.8 (3.62)	50	70.4 (3.83)	-1.0 (4.11)
Wk 16	68	71.2 (4.57)	0.4 (4.39)	42	69.3 (4.79)	-0.5 (4.27)	37	70.5 (4.93)	-1.0 (4.57)
Wk 20	66	70.0 (4.92)	-1.1 (4.53)	31	68.7 (4.82)	-1.3 (3.88)	31	69.5 (4.15)	-1.8 (4.13)
Wk 24	57	70.1 (4.33)	-0.8 (4.81)	27	70.9 (6.11)	0.7 (4.03)	30	70.7 (3.47)	-0.7 (3.83)
Wk 26	57	70.4 (4.48)	-0.5 (4.56)	25	69.4 (5.29)	-1.1 (4.26)	27	69.4 (4.89)	-2.5 (4.01)
End[1]	84	70.2 (4.26)	-0.3 (4.35)	82	70.1 (4.95)	-0.4 (3.97)	80	70.4 (3.91)	-0.7 (3.63)
SODIUM									
Bsln	86	140.3 (2.74)		82	140.0 (2.61)		83	140.0 (3.11)	
Wk 2	84	140.4 (2.62)	-0.0 (3.35)	80	139.6 (2.47)	-0.3 (2.86)	77	139.1 (2.74)	-0.6 (2.87)
Wk 4	82	139.9 (2.74)	-0.4 (3.58)	72	140.1 (2.40)	0.2 (3.16)	72	139.7 (2.75)	-0.3 (3.39)
Wk 6	75	140.3 (2.58)	0.0 (3.08)	64	140.6 (2.69)	0.8 (3.25)	67	140.1 (2.61)	-0.2 (3.23)
Wk 8	73	140.7 (2.48)	0.4 (3.33)	60	140.5 (2.58)	0.6 (3.33)	56	140.5 (3.15)	0.3 (3.79)
Wk 12	67	140.4 (2.39)	0.2 (2.98)	52	141.1 (2.77)	1.1 (3.06)	49	140.2 (2.39)	-0.1 (2.79)
Wk 16	68	141.1 (2.37)	0.9 (3.10)	42	141.0 (2.62)	1.2 (2.93)	37	141.6 (2.96)	1.4 (3.18)
Wk 20	65	141.2 (2.53)	1.1 (3.01)	31	141.4 (2.53)	1.6 (3.42)	31	141.8 (3.87)	1.2 (3.61)
Wk 24	57	141.7 (2.23)	1.6 (3.27)	27	141.5 (2.12)	1.2 (3.12)	30	141.6 (2.99)	1.0 (3.10)
Wk 26	57	142.6 (2.25)	2.5 (2.90)	25	142.1 (2.08)	1.9 (3.13)	27	142.4 (3.07)	1.9 (3.43)
End[1]	84	141.5 (2.74)	1.1 (3.51)	82	141.1 (2.65)	1.3 (3.09)	80	140.5 (3.22)	0.5 (3.50)

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Visit	Placebo			Xanomeline Low			Xanomeline High		
	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)
URATE									
Bsln	86	285.0 (74.45)		82	300.7 (77.78)		84	302.2 (78.01)	
Wk 2	84	284.0 (68.72)	-1.8 (50.16)	80	305.8 (74.25)	1.0 (40.56)	78	301.7 (81.96)	-2.7 (33.85)
Wk 4	82	285.6 (69.22)	-0.6 (35.59)	72	299.5 (79.44)	-3.7 (38.80)	72	291.4 (79.28)	-9.5 (42.17)
Wk 6	75	288.0 (68.73)	-1.1 (38.24)	64	298.1 (74.46)	-6.2 (30.89)	67	291.6 (74.82)	-9.8 (34.48)
Wk 8	73	285.6 (65.63)	-5.1 (36.28)	60	290.9 (71.15)	-15.6 (30.49)	56	291.6 (76.76)	-11.2 (35.13)
Wk 12	67	291.1 (70.07)	3.2 (40.20)	52	290.3 (63.20)	-11.5 (31.83)	50	294.2 (78.84)	-9.0 (36.29)
Wk 16	68	285.8 (68.72)	-3.6 (41.33)	42	288.8 (58.78)	-12.9 (39.98)	37	284.1 (80.47)	-19.9 (36.13)
Wk 20	66	301.9 (73.43)	12.1 (40.18)	31	279.7 (58.71)	-16.5 (44.34)	31	295.1 (85.89)	-9.6 (43.81)
Wk 24	57	293.5 (73.47)	4.6 (42.98)	27	274.9 (57.72)	-19.2 (31.26)	30	288.5 (88.37)	-19.4 (50.03)
Wk 26	57	291.9 (74.43)	5.1 (44.39)	25	279.3 (60.01)	-13.6 (39.12)	27	301.1 (86.31)	-12.6 (47.68)
End[1]	84	290.5 (73.86)	4.7 (46.43)	82	298.3 (80.54)	-3.1 (37.11)	80	292.4 (80.83)	-10.5 (42.35)
UREA NITROGEN									
Bsln	86	5.5 (1.39)		82	6.4 (1.97)		84	5.8 (1.88)	
Wk 2	84	5.8 (1.51)	0.3 (1.17)	80	6.6 (1.82)	0.3 (1.53)	78	6.0 (2.06)	0.3 (1.36)
Wk 4	82	5.9 (1.47)	0.3 (1.11)	72	6.4 (1.63)	0.0 (1.37)	72	5.9 (1.87)	0.3 (1.30)
Wk 6	75	6.1 (1.42)	0.5 (1.16)	64	6.4 (1.76)	-0.1 (1.32)	67	6.0 (2.06)	0.3 (1.43)
Wk 8	73	5.6 (1.58)	-0.0 (1.22)	60	6.3 (1.92)	-0.0 (0.95)	56	5.9 (1.93)	0.1 (1.25)
Wk 12	67	5.9 (1.61)	0.2 (1.24)	52	6.2 (1.49)	-0.0 (1.45)	50	5.9 (1.76)	0.1 (1.50)
Wk 16	68	5.8 (1.60)	0.2 (1.28)	42	6.0 (1.62)	-0.2 (1.25)	37	5.7 (1.92)	0.2 (1.29)
Wk 20	66	5.8 (1.53)	0.1 (1.28)	31	5.6 (1.57)	-0.6 (1.39)	31	5.9 (2.25)	0.2 (1.50)
Wk 24	57	5.9 (1.32)	0.3 (1.24)	27	6.0 (2.07)	-0.0 (1.37)	30	5.3 (1.92)	-0.3 (1.37)
Wk 26	57	6.1 (1.62)	0.4 (1.36)	25	5.7 (1.93)	-0.3 (1.14)	27	5.9 (2.47)	0.3 (1.40)
End[1]	84	5.9 (1.38)	0.3 (1.20)	82	6.6 (1.95)	0.2 (1.37)	80	5.7 (1.97)	-0.0 (1.57)

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High			
Visit	N	Mean (SD)	Change	N	Mean (SD)	Change	N	Mean (SD)	Change		
			from Bsln Mean (SD)			from Bsln Mean (SD)			from Bsln Mean (SD)		
HEMATOLOGY											
BASOPHILS											
Bsln	85	0.1 (0.04)		81	0.1 (0.03)		81	0.1 (0.02)			
Wk 2	83	0.0 (0.02)	-0.0 (0.03)	80	0.1 (0.03)	-0.0 (0.03)	80	0.0 (0.03)	-0.0 (0.02)		
Wk 4	79	0.0 (0.02)	-0.0 (0.03)	71	0.0 (0.03)	-0.0 (0.03)	71	0.0 (0.02)	-0.0 (0.02)		
Wk 6	73	0.0 (0.03)	-0.0 (0.03)	62	0.0 (0.03)	-0.0 (0.03)	64	0.1 (0.03)	0.0 (0.03)		
Wk 8	72	0.0 (0.02)	-0.0 (0.03)	59	0.1 (0.02)	-0.0 (0.04)	56	0.1 (0.03)	0.0 (0.02)		
Wk 12	66	0.0 (0.02)	-0.0 (0.04)	50	0.0 (0.02)	-0.0 (0.03)	50	0.1 (0.03)	-0.0 (0.02)		
Wk 16	68	0.0 (0.03)	-0.0 (0.04)	42	0.0 (0.02)	-0.0 (0.03)	37	0.1 (0.03)	-0.0 (0.02)		
Wk 20	65	0.0 (0.03)	-0.0 (0.03)	30	0.0 (0.02)	-0.0 (0.03)	31	0.0 (0.02)	-0.0 (0.03)		
Wk 24	58	0.0 (0.03)	-0.0 (0.03)	25	0.0 (0.03)	-0.0 (0.02)	30	0.1 (0.02)	-0.0 (0.02)		
Wk 26	57	0.0 (0.02)	-0.0 (0.03)	25	0.0 (0.03)	-0.0 (0.02)	27	0.1 (0.03)	-0.0 (0.03)		
End[1]	84	0.0 (0.03)	-0.0 (0.03)	82	0.0 (0.03)	-0.0 (0.03)	81	0.1 (0.02)	-0.0 (0.02)		
EOSINOPHILS											
Bsln	85	0.1 (0.12)		81	0.1 (0.12)		81	0.1 (0.10)			
Wk 2	83	0.1 (0.10)	-0.0 (0.09)	80	0.2 (0.17)	0.0 (0.14)	80	0.1 (0.11)	-0.0 (0.07)		
Wk 4	79	0.1 (0.13)	-0.0 (0.09)	71	0.2 (0.14)	0.0 (0.11)	71	0.2 (0.15)	0.0 (0.13)		
Wk 6	73	0.1 (0.13)	-0.0 (0.11)	62	0.2 (0.21)	0.1 (0.16)	64	0.2 (0.28)	0.1 (0.25)		
Wk 8	72	0.1 (0.10)	-0.0 (0.10)	59	0.3 (0.26)	0.2 (0.23)	56	0.2 (0.25)	0.1 (0.19)		
Wk 12	66	0.1 (0.09)	-0.0 (0.11)	50	0.3 (0.21)	0.1 (0.19)	50	0.2 (0.17)	0.1 (0.14)		
Wk 16	68	0.1 (0.08)	-0.0 (0.10)	42	0.2 (0.16)	0.1 (0.13)	37	0.2 (0.21)	0.1 (0.17)		
Wk 20	65	0.1 (0.08)	-0.0 (0.10)	30	0.2 (0.19)	0.1 (0.16)	31	0.1 (0.11)	0.0 (0.12)		
Wk 24	58	0.1 (0.08)	-0.0 (0.09)	25	0.2 (0.14)	0.0 (0.12)	30	0.2 (0.15)	0.0 (0.13)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo					Xanomeline Low					Xanomeline High				
Visit	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)	Change from Bsln Mean (SD)	N	Mean (SD)
Wk 26	57	0.1 (0.10)	-0.0 (0.11)	25	0.2 (0.15)	0.0 (0.13)	27	0.1 (0.10)	0.0 (0.09)					
End[1]	84	0.1 (0.08)	-0.0 (0.10)	82	0.2 (0.17)	0.0 (0.14)	81	0.2 (0.20)	0.1 (0.18)					
ERY. MEAN CORPUSCULAR HB CONCENTRATION														
Bsln	85	20.6 (0.87)		80	20.2 (0.98)		80	20.5 (0.87)						
Wk 2	83	20.3 (0.77)	-0.3 (1.00)	80	20.3 (0.85)	0.0 (1.04)	80	20.4 (0.74)	-0.0 (0.98)					
Wk 4	77	20.2 (0.78)	-0.4 (1.01)	69	20.2 (0.72)	-0.0 (0.94)	70	20.5 (0.71)	-0.1 (0.90)					
Wk 6	72	20.5 (0.77)	-0.2 (0.98)	60	20.1 (0.84)	-0.2 (0.99)	65	20.4 (0.89)	-0.2 (1.00)					
Wk 8	71	20.3 (0.68)	-0.2 (0.85)	56	20.2 (0.83)	-0.0 (0.92)	56	20.5 (0.76)	-0.1 (0.93)					
Wk 12	65	20.3 (0.74)	-0.3 (0.96)	49	20.3 (0.68)	-0.0 (0.99)	50	20.5 (0.76)	-0.1 (1.03)					
Wk 16	68	20.2 (0.75)	-0.4 (1.02)	42	20.0 (0.82)	-0.2 (1.02)	37	20.4 (0.83)	-0.2 (1.11)					
Wk 20	64	20.3 (0.80)	-0.3 (0.94)	30	20.0 (0.85)	-0.4 (0.91)	31	20.3 (0.88)	-0.3 (1.22)					
Wk 24	58	20.1 (0.89)	-0.5 (1.01)	25	20.3 (0.91)	-0.3 (0.95)	30	20.4 (0.85)	-0.3 (1.29)					
Wk 26	56	20.3 (0.99)	-0.4 (1.16)	25	19.9 (0.94)	-0.6 (1.09)	27	20.2 (0.92)	-0.6 (1.12)					
End[1]	83	20.2 (0.85)	-0.4 (0.99)	82	20.2 (0.81)	-0.0 (0.98)	81	20.4 (0.78)	-0.1 (1.08)					
ERY. MEAN CORPUSCULAR HEMOGLOBIN														
Bsln	85	1.9 (0.12)		81	1.9 (0.09)		81	1.9 (0.13)						
Wk 2	83	1.9 (0.11)	-0.0 (0.07)	80	1.9 (0.09)	0.0 (0.07)	80	1.9 (0.13)	-0.0 (0.07)					
Wk 4	79	1.9 (0.12)	-0.0 (0.07)	71	1.9 (0.09)	0.0 (0.07)	71	1.9 (0.13)	-0.0 (0.06)					
Wk 6	73	1.9 (0.13)	0.0 (0.08)	62	1.9 (0.08)	0.0 (0.05)	65	1.9 (0.13)	-0.0 (0.08)					
Wk 8	72	1.9 (0.12)	0.0 (0.06)	59	1.9 (0.09)	0.0 (0.06)	56	1.9 (0.10)	-0.0 (0.07)					
Wk 12	66	1.9 (0.12)	0.0 (0.06)	50	1.9 (0.09)	0.0 (0.05)	50	1.9 (0.09)	-0.0 (0.07)					
Wk 16	68	1.9 (0.12)	-0.0 (0.05)	42	1.9 (0.10)	-0.0 (0.07)	37	1.9 (0.11)	-0.0 (0.08)					
Wk 20	65	1.9 (0.11)	-0.0 (0.06)	30	1.9 (0.08)	0.0 (0.06)	31	1.9 (0.12)	-0.0 (0.08)					
Wk 24	58	1.9 (0.12)	-0.0 (0.06)	25	1.9 (0.09)	-0.0 (0.06)	30	1.9 (0.13)	-0.0 (0.09)					
Wk 26	57	1.9 (0.12)	-0.0 (0.07)	25	1.9 (0.08)	-0.0 (0.08)	27	1.9 (0.12)	-0.0 (0.08)					

[1] Last observed value while on treatment (prior to or at Week 24)

locf

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo					Xanomeline Low					Xanomeline High						
					Change from Bsln					Change from Bsln					Change from Bsln	
Visit	N	Mean	(SD)	Mean	(SD)	N	Mean	(SD)	Mean	(SD)	N	Mean	(SD)	Mean	(SD)	
End[1]	84	1.9	(0.12)	-0.0	(0.07)	82	1.9	(0.09)	0.0	(0.06)	81	1.9	(0.13)	0.0	(0.07)	
ERY. MEAN CORPUSCULAR VOLUME																
Bsln	85	92.9	(5.69)			80	94.6	(4.90)			80	93.3	(5.91)			
Wk 2	83	94.1	(5.31)	1.2	(3.93)	80	94.6	(4.12)	0.2	(3.57)	80	93.4	(5.93)	0.2	(3.91)	
Wk 4	77	94.6	(5.87)	1.7	(3.47)	69	95.1	(4.22)	0.6	(3.69)	70	93.0	(5.52)	0.0	(3.69)	
Wk 6	72	94.2	(6.21)	1.3	(3.79)	60	95.2	(4.51)	0.7	(3.68)	65	94.0	(6.61)	0.6	(3.99)	
Wk 8	71	94.3	(5.51)	1.5	(3.27)	56	94.9	(3.97)	0.6	(3.35)	56	94.4	(4.77)	0.4	(4.03)	
Wk 12	65	94.2	(5.66)	1.6	(3.81)	49	95.1	(4.17)	0.9	(3.91)	50	94.9	(4.90)	0.8	(4.20)	
Wk 16	68	94.1	(6.01)	1.7	(4.07)	42	95.8	(5.17)	1.2	(4.18)	37	94.7	(6.27)	0.6	(5.05)	
Wk 20	64	93.3	(5.58)	1.3	(4.14)	30	95.4	(5.43)	2.0	(3.29)	31	95.1	(5.91)	0.9	(5.12)	
Wk 24	58	93.9	(5.90)	1.6	(3.85)	25	94.3	(3.85)	0.8	(3.94)	30	95.0	(5.99)	0.7	(4.97)	
Wk 26	56	93.9	(6.40)	1.7	(4.48)	25	95.8	(4.33)	2.6	(3.70)	27	95.4	(6.19)	1.2	(3.93)	
End[1]	83	94.4	(5.93)	1.4	(4.07)	82	95.0	(3.98)	0.6	(3.83)	81	93.8	(6.14)	0.7	(4.40)	
ERYTHROCYTES																
Bsln	85	4.5	(0.45)			81	4.5	(0.42)			81	4.7	(0.47)			
Wk 2	83	4.4	(0.40)	-0.1	(0.22)	80	4.4	(0.43)	-0.1	(0.27)	80	4.6	(0.47)	-0.1	(0.22)	
Wk 4	79	4.4	(0.45)	-0.1	(0.25)	71	4.4	(0.38)	-0.2	(0.30)	71	4.5	(0.49)	-0.1	(0.25)	
Wk 6	73	4.4	(0.37)	-0.1	(0.24)	62	4.3	(0.38)	-0.2	(0.27)	65	4.5	(0.50)	-0.1	(0.24)	
Wk 8	72	4.4	(0.41)	-0.1	(0.26)	59	4.4	(0.34)	-0.2	(0.24)	56	4.5	(0.45)	-0.1	(0.19)	
Wk 12	66	4.4	(0.44)	-0.1	(0.26)	50	4.3	(0.32)	-0.2	(0.20)	50	4.6	(0.47)	-0.1	(0.27)	
Wk 16	68	4.5	(0.41)	-0.0	(0.27)	42	4.3	(0.36)	-0.1	(0.24)	37	4.6	(0.44)	-0.2	(0.26)	
Wk 20	65	4.5	(0.41)	-0.1	(0.30)	30	4.3	(0.32)	-0.1	(0.21)	31	4.5	(0.50)	-0.2	(0.30)	
Wk 24	58	4.4	(0.45)	-0.1	(0.23)	25	4.4	(0.38)	-0.1	(0.19)	30	4.6	(0.58)	-0.1	(0.24)	
Wk 26	57	4.4	(0.42)	-0.0	(0.25)	25	4.4	(0.35)	-0.1	(0.20)	27	4.5	(0.47)	-0.2	(0.27)	
End[1]	84	4.4	(0.43)	-0.1	(0.27)	82	4.4	(0.38)	-0.2	(0.25)	81	4.6	(0.49)	-0.1	(0.22)	

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High			
Visit	N	Mean (SD)	Change	N	Mean (SD)	Change	N	Mean (SD)	Change		
			from Bsln Mean (SD)			from Bsln Mean (SD)			from Bsln Mean (SD)		
HEMATOCRIT											
Bsln	85	0.4 (0.04)		80	0.4 (0.04)		80	0.4 (0.04)			
Wk 2	83	0.4 (0.04)	-0.0 (0.03)	80	0.4 (0.04)	-0.0 (0.03)	80	0.4 (0.04)	-0.0 (0.03)		
Wk 4	77	0.4 (0.04)	-0.0 (0.03)	69	0.4 (0.04)	-0.0 (0.03)	70	0.4 (0.04)	-0.0 (0.03)		
Wk 6	72	0.4 (0.04)	-0.0 (0.03)	60	0.4 (0.04)	-0.0 (0.03)	65	0.4 (0.04)	-0.0 (0.03)		
Wk 8	71	0.4 (0.04)	-0.0 (0.03)	56	0.4 (0.03)	-0.0 (0.02)	56	0.4 (0.03)	-0.0 (0.03)		
Wk 12	65	0.4 (0.04)	-0.0 (0.03)	49	0.4 (0.03)	-0.0 (0.02)	50	0.4 (0.04)	-0.0 (0.03)		
Wk 16	68	0.4 (0.04)	0.0 (0.03)	42	0.4 (0.03)	-0.0 (0.03)	37	0.4 (0.03)	-0.0 (0.04)		
Wk 20	64	0.4 (0.04)	-0.0 (0.03)	30	0.4 (0.03)	-0.0 (0.02)	31	0.4 (0.04)	-0.0 (0.04)		
Wk 24	58	0.4 (0.04)	0.0 (0.03)	25	0.4 (0.04)	-0.0 (0.02)	30	0.4 (0.04)	-0.0 (0.04)		
Wk 26	56	0.4 (0.04)	0.0 (0.03)	25	0.4 (0.04)	-0.0 (0.03)	27	0.4 (0.04)	-0.0 (0.03)		
End[1]	83	0.4 (0.04)	-0.0 (0.03)	82	0.4 (0.04)	-0.0 (0.03)	81	0.4 (0.04)	-0.0 (0.03)		
HEMOGLOBIN											
Bsln	85	8.6 (0.83)		81	8.6 (0.77)		81	8.9 (0.78)			
Wk 2	83	8.4 (0.76)	-0.2 (0.42)	80	8.4 (0.76)	-0.2 (0.46)	80	8.7 (0.83)	-0.2 (0.42)		
Wk 4	79	8.4 (0.82)	-0.2 (0.44)	71	8.4 (0.78)	-0.3 (0.50)	71	8.6 (0.78)	-0.2 (0.45)		
Wk 6	73	8.4 (0.77)	-0.2 (0.44)	62	8.3 (0.76)	-0.3 (0.46)	65	8.6 (0.75)	-0.3 (0.44)		
Wk 8	72	8.5 (0.76)	-0.2 (0.46)	59	8.3 (0.71)	-0.3 (0.39)	56	8.7 (0.73)	-0.3 (0.39)		
Wk 12	66	8.4 (0.83)	-0.2 (0.42)	50	8.3 (0.69)	-0.3 (0.34)	50	8.8 (0.79)	-0.3 (0.42)		
Wk 16	68	8.5 (0.73)	-0.1 (0.46)	42	8.3 (0.69)	-0.2 (0.42)	37	8.7 (0.70)	-0.3 (0.47)		
Wk 20	65	8.4 (0.80)	-0.2 (0.51)	30	8.2 (0.63)	-0.2 (0.46)	31	8.7 (0.79)	-0.4 (0.46)		
Wk 24	58	8.3 (0.82)	-0.2 (0.40)	25	8.4 (0.69)	-0.2 (0.36)	30	8.9 (0.85)	-0.3 (0.36)		
Wk 26	57	8.4 (0.80)	-0.2 (0.47)	25	8.3 (0.67)	-0.3 (0.39)	27	8.7 (0.74)	-0.5 (0.39)		
End[1]	84	8.4 (0.78)	-0.2 (0.44)	82	8.4 (0.69)	-0.2 (0.44)	81	8.7 (0.79)	-0.2 (0.36)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

Placebo				Xanomeline Low				Xanomeline High			
Visit	N	Mean (SD)	Change	N	Mean (SD)	Change	N	Mean (SD)	Change		
			from Bsln Mean (SD)			from Bsln Mean (SD)			from Bsln Mean (SD)		
LEUKOCYTES											
Bsln	85	6.9 (1.76)		81	6.6 (1.95)		81	6.5 (1.54)			
Wk 2	83	6.5 (1.55)	-0.4 (1.40)	80	6.9 (1.99)	0.2 (1.37)	80	6.5 (1.59)	-0.1 (1.18)		
Wk 4	79	6.4 (1.63)	-0.4 (1.17)	71	6.8 (2.12)	0.1 (1.53)	71	6.6 (1.42)	0.1 (1.21)		
Wk 6	73	6.5 (1.57)	-0.4 (1.36)	62	6.9 (1.99)	0.1 (1.14)	65	7.0 (1.84)	0.4 (1.65)		
Wk 8	72	6.5 (1.70)	-0.3 (1.28)	59	7.1 (1.88)	0.3 (1.26)	56	6.9 (1.95)	0.4 (1.64)		
Wk 12	66	6.3 (1.28)	-0.5 (1.09)	50	6.8 (2.03)	0.2 (0.97)	50	6.6 (1.51)	-0.0 (1.21)		
Wk 16	68	6.4 (1.50)	-0.5 (1.29)	42	6.6 (2.11)	0.2 (1.44)	37	6.8 (1.72)	-0.1 (1.37)		
Wk 20	65	6.5 (1.77)	-0.5 (1.40)	30	6.5 (1.94)	0.1 (1.24)	31	6.6 (1.67)	-0.2 (1.21)		
Wk 24	58	6.7 (1.77)	-0.2 (1.37)	25	6.3 (1.84)	0.0 (1.16)	30	6.7 (1.80)	-0.1 (1.16)		
Wk 26	57	6.4 (1.47)	-0.4 (1.24)	25	6.1 (1.93)	-0.3 (1.15)	27	6.7 (1.78)	-0.2 (1.42)		
End[1]	84	6.6 (1.80)	-0.2 (1.32)	82	6.8 (2.17)	0.1 (1.35)	81	6.7 (1.76)	0.2 (1.37)		
LYMPHOCYTES											
Bsln	85	1.8 (0.57)		81	1.8 (0.57)		81	1.7 (0.52)			
Wk 2	83	1.7 (0.50)	-0.1 (0.37)	80	1.8 (0.66)	0.0 (0.45)	80	1.7 (0.50)	0.0 (0.38)		
Wk 4	79	1.7 (0.56)	-0.0 (0.38)	71	1.8 (0.67)	0.0 (0.49)	71	1.7 (0.50)	-0.0 (0.44)		
Wk 6	73	1.8 (0.58)	-0.0 (0.41)	62	1.9 (0.64)	0.1 (0.47)	64	1.7 (0.48)	-0.0 (0.44)		
Wk 8	72	1.8 (0.67)	-0.0 (0.44)	59	1.9 (0.65)	0.1 (0.45)	56	1.7 (0.50)	-0.0 (0.36)		
Wk 12	66	1.7 (0.58)	-0.1 (0.42)	50	1.8 (0.58)	-0.1 (0.45)	50	1.6 (0.47)	-0.0 (0.37)		
Wk 16	68	1.7 (0.58)	-0.1 (0.42)	42	1.8 (0.63)	-0.1 (0.34)	37	1.7 (0.62)	0.0 (0.41)		
Wk 20	65	1.7 (0.50)	-0.1 (0.45)	30	1.7 (0.59)	-0.1 (0.50)	31	1.7 (0.59)	-0.0 (0.36)		
Wk 24	58	1.8 (0.65)	-0.0 (0.48)	25	1.8 (0.56)	-0.1 (0.37)	30	1.7 (0.56)	-0.0 (0.37)		
Wk 26	57	1.8 (0.59)	-0.0 (0.43)	25	1.7 (0.62)	-0.1 (0.39)	27	1.8 (0.61)	0.1 (0.50)		
End[1]	84	1.8 (0.59)	-0.0 (0.46)	82	1.8 (0.62)	-0.0 (0.46)	81	1.6 (0.54)	-0.0 (0.38)		

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPilot01
Population: Safety

Page 15 of 15

Table 14-6.01
Summary Statistics for Continuous Laboratory Values

	Placebo				Xanomeline Low				Xanomeline High			
	Change				Change				Change			
	from Bsln				from Bsln				from Bsln			
Visit	N	Mean	(SD)	Mean (SD)	N	Mean	(SD)	Mean (SD)	N	Mean	(SD)	Mean (SD)
MONOCYTES												
Bsln	85	0.4	(0.15)		81	0.5	(0.16)		81	0.4	(0.12)	
Wk 2	83	0.4	(0.15)	-0.0 (0.14)	80	0.5	(0.16)	0.0 (0.13)	80	0.4	(0.15)	0.0 (0.12)
Wk 4	79	0.4	(0.12)	0.0 (0.11)	71	0.5	(0.17)	-0.0 (0.15)	71	0.4	(0.13)	0.0 (0.13)
Wk 6	73	0.4	(0.15)	-0.0 (0.13)	62	0.5	(0.19)	0.0 (0.16)	64	0.5	(0.15)	0.0 (0.13)
Wk 8	72	0.4	(0.14)	0.0 (0.14)	59	0.5	(0.14)	0.0 (0.14)	56	0.5	(0.15)	0.0 (0.14)
Wk 12	66	0.4	(0.13)	0.0 (0.13)	50	0.5	(0.15)	0.0 (0.12)	50	0.4	(0.15)	-0.0 (0.11)
Wk 16	68	0.5	(0.15)	0.0 (0.17)	42	0.5	(0.16)	0.0 (0.12)	37	0.5	(0.16)	0.0 (0.14)
Wk 20	65	0.5	(0.16)	0.0 (0.15)	30	0.5	(0.13)	0.0 (0.13)	31	0.5	(0.17)	0.0 (0.18)
Wk 24	58	0.5	(0.17)	0.0 (0.17)	25	0.5	(0.19)	0.0 (0.11)	30	0.5	(0.18)	-0.0 (0.12)
Wk 26	57	0.4	(0.14)	0.0 (0.14)	25	0.4	(0.17)	-0.0 (0.12)	27	0.5	(0.14)	-0.0 (0.13)
End[1]	84	0.5	(0.17)	0.0 (0.17)	82	0.5	(0.17)	0.0 (0.13)	81	0.5	(0.15)	0.0 (0.12)
PLATELET												
Bsln	84	250.3	(65.52)		79	233.8	(58.58)		81	227.7	(54.74)	
Wk 2	83	246.2	(57.55)	-4.4 (36.21)	78	247.4	(59.37)	9.1 (46.36)	80	238.2	(59.77)	8.4 (31.55)
Wk 4	78	243.8	(54.30)	-7.4 (40.04)	70	239.2	(57.80)	5.7 (39.75)	70	238.3	(49.60)	9.8 (29.21)
Wk 6	73	250.8	(58.97)	-3.3 (36.82)	62	238.3	(55.74)	3.5 (43.39)	63	239.1	(56.79)	9.2 (37.82)
Wk 8	72	246.0	(66.61)	-6.2 (42.35)	59	245.4	(60.21)	5.1 (46.18)	55	236.9	(70.88)	11.0 (48.13)
Wk 12	65	241.9	(53.71)	-12.8 (42.62)	50	238.8	(49.49)	1.9 (24.69)	49	236.1	(53.03)	9.1 (34.47)
Wk 16	68	241.8	(55.65)	-13.7 (43.45)	41	244.5	(57.60)	2.8 (32.93)	37	230.9	(58.00)	5.3 (25.87)
Wk 20	65	248.4	(60.70)	-8.4 (30.42)	30	240.7	(64.07)	7.3 (42.65)	30	235.1	(65.46)	2.3 (22.80)
Wk 24	57	238.8	(51.89)	-11.3 (35.06)	24	249.7	(63.44)	1.8 (33.48)	29	238.3	(67.53)	4.5 (26.74)
Wk 26	56	247.6	(60.11)	-2.7 (41.73)	25	241.3	(57.16)	-1.9 (38.84)	27	237.4	(67.14)	0.3 (26.99)
End[1]	84	241.5	(59.49)	-8.5 (35.55)	82	236.7	(63.56)	1.1 (36.31)	81	233.8	(60.79)	4.1 (35.89)

[1] Last observed value while on treatment (prior to or at Week 24)

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_lb_cont.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPILOT01

Population: Safety

Table 14-6.02

Frequency of Normal and Abnormal (Beyond Normal Range) Laboratory Values During Treatment

	Placebo (N=86)			Xan. Low (N=84)			Xan. High (N=84)			p-val [1]	
	Low	Normal	High	Low	Normal	High	Low	Normal	High		
CHEMISTRY											

ALBUMIN	16 (19%)	65 (77%)	3 (4%)	15 (18%)	66 (80%)	1 (1%)	5 (6%)	74 (93%)	1 (1%)	0.042	
ALKALINE	4 (5%)	72 (86%)	8 (10%)	2 (2%)	74 (90%)	6 (7%)	3 (4%)	73 (91%)	4 (5%)	0.776	
PHOSPHATASE											
ALANINE	1 (1%)	74 (88%)	9 (11%)	5 (6%)	68 (83%)	9 (11%)	0	70 (88%)	10 (13%)	0.185	
AMINOTRANSFERASE											
ASPARTATE	0	74 (88%)	10 (12%)	0	72 (88%)	10 (12%)	0	72 (90%)	8 (10%)	0.907	
AMINOTRANSFERASE											
BILIRUBIN	0	78 (93%)	6 (7%)	0	79 (98%)	2 (2%)	0	75 (94%)	5 (6%)	0.402	
UREA NITROGEN	0	75 (89%)	9 (11%)	0	60 (73%)	22 (27%)	0	68 (85%)	12 (15%)	0.023	
CALCIUM	5 (6%)	78 (93%)	1 (1%)	7 (9%)	72 (88%)	3 (4%)	7 (9%)	71 (89%)	2 (3%)	0.789	
CHOLESTEROL	5 (6%)	73 (87%)	6 (7%)	6 (7%)	72 (88%)	4 (5%)	6 (8%)	70 (88%)	4 (5%)	0.962	
CREATINE KINASE	1 (1%)	66 (79%)	17 (20%)	1 (1%)	68 (83%)	13 (16%)	0	67 (84%)	13 (16%)	0.816	
CHLORIDE	0	74 (88%)	10 (12%)	0	74 (90%)	8 (10%)	0	78 (98%)	2 (3%)	0.058	
CREATININE	0	80 (95%)	4 (5%)	0	76 (93%)	6 (7%)	0	73 (91%)	7 (9%)	0.572	
GAMMA GLUTAMYL	4 (5%)	73 (87%)	7 (8%)	4 (5%)	69 (84%)	9 (11%)	1 (1%)	71 (89%)	8 (10%)	0.689	
TRANSFERASE											
GLUCOSE	0	82 (98%)	2 (2%)	0	81 (99%)	1 (1%)	0	77 (96%)	3 (4%)	0.534	
POTASSIUM	3 (4%)	80 (95%)	1 (1%)	3 (4%)	79 (96%)	0	2 (3%)	78 (98%)	0	1.000	
SODIUM	4 (5%)	75 (89%)	5 (6%)	3 (4%)	74 (90%)	5 (6%)	7 (9%)	62 (78%)	11 (14%)	0.177	
PHOSPHATE	1 (1%)	83 (99%)	0	0	80 (98%)	2 (2%)	1 (1%)	78 (98%)	1 (1%)	0.518	
PROTEIN	1 (1%)	76 (90%)	7 (8%)	2 (2%)	75 (91%)	5 (6%)	1 (1%)	77 (96%)	2 (3%)	0.536	
URATE	3 (4%)	77 (92%)	4 (5%)	1 (1%)	75 (91%)	6 (7%)	4 (5%)	69 (86%)	7 (9%)	0.564	
HEMATOLOGY											

Note: Percentages are based on the number of subjects with non-missing assessments (i.e., the total of the subjects in the low, normal, and high categories) within each treatment group.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labnormfreq.sas

21:05 Monday, June 26, 2006

Table 14-6.02

Frequency of Normal and Abnormal (Beyond Normal Range) Laboratory Values During Treatment

	Placebo (N=86)			Xan. Low (N=84)			Xan. High (N=84)			p-val [1]
	Low	Normal	High	Low	Normal	High	Low	Normal	High	
BASOPHILS	0	84 (100%)	0	0	82 (100%)	0	0	81 (100%)	0	
EOSINOPHILS	0	84 (100%)	0	0	71 (87%)	11 (13%)	0	74 (91%)	7 (9%)	0.001
HEMATOCRIT	5 (6%)	74 (89%)	4 (5%)	9 (11%)	72 (88%)	1 (1%)	1 (1%)	78 (96%)	2 (2%)	0.052
HEMOGLOBIN	14 (17%)	68 (81%)	2 (2%)	10 (12%)	72 (88%)	0	5 (6%)	73 (90%)	3 (4%)	0.093
LYMPHOCYTES	6 (7%)	73 (87%)	5 (6%)	4 (5%)	69 (84%)	9 (11%)	4 (5%)	76 (94%)	1 (1%)	0.103
ERY. MEAN	0	81 (96%)	3 (4%)	0	81 (99%)	1 (1%)	1 (1%)	75 (93%)	5 (6%)	0.186
CORPUSCULAR										
HEMOGLOBIN										
ERY. MEAN	15 (18%)	68 (82%)	0	17 (21%)	65 (79%)	0	9 (11%)	72 (89%)	0	0.231
CORPUSCULAR HB										
CONCENTRATION										
ERY. MEAN	1 (1%)	53 (64%)	29 (35%)	0	64 (78%)	18 (22%)	1 (1%)	64 (79%)	16 (20%)	0.077
CORPUSCULAR VOLUME										
MONOCYTES	2 (2%)	80 (95%)	2 (2%)	1 (1%)	77 (94%)	4 (5%)	0	79 (98%)	2 (2%)	0.626
PLATELET	0	81 (96%)	3 (4%)	2 (2%)	77 (94%)	3 (4%)	2 (2%)	77 (95%)	2 (2%)	0.681
ERYTHROCYTES	13 (15%)	71 (85%)	0	18 (22%)	64 (78%)	0	11 (14%)	68 (84%)	2 (2%)	0.238
LEUKOCYTES	7 (8%)	73 (87%)	4 (5%)	6 (7%)	68 (83%)	8 (10%)	4 (5%)	74 (91%)	3 (4%)	0.462

Note: Percentages are based on the number of subjects with non-missing assessments (i.e., the total of the subjects in the low, normal, and high categories) within each treatment group.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labnormfreq.sas

21:05 Monday, June 26, 2006

Table 14-6.03

Frequency of Normal and Abnormal (Clinically Significant Change from Previous Visit) Laboratory Values During Treatment

	Placebo (N=86)			Xan. Low (N=84)			Xan. High (N=84)			p-val [1]
	Low	Normal	High	Low	Normal	High	Low	Normal	High	
CHEMISTRY										

ALBUMIN	10 (12%)	71 (85%)	3 (4%)	6 (7%)	72 (88%)	4 (5%)	5 (6%)	66 (83%)	9 (11%)	0.235
ALKALINE PHOSPHATASE	1 (1%)	78 (93%)	5 (6%)	0	79 (98%)	2 (2%)	0	77 (96%)	3 (4%)	0.599
ALANINE AMINOTRANSFERASE	4 (5%)	75 (89%)	5 (6%)	6 (7%)	69 (84%)	7 (9%)	7 (9%)	68 (85%)	5 (6%)	0.820
ASPARTATE AMINOTRANSFERASE	2 (2%)	73 (87%)	9 (11%)	8 (10%)	71 (87%)	3 (4%)	3 (4%)	75 (94%)	2 (3%)	0.045
BILIRUBIN	0	79 (94%)	5 (6%)	1 (1%)	79 (98%)	1 (1%)	2 (3%)	75 (94%)	3 (4%)	0.296
UREA NITROGEN	0	83 (99%)	1 (1%)	1 (1%)	79 (96%)	2 (2%)	1 (1%)	78 (98%)	1 (1%)	0.796
CALCIUM	6 (7%)	76 (90%)	2 (2%)	4 (5%)	76 (93%)	2 (2%)	0	77 (96%)	3 (4%)	0.140
CHOLESTEROL	1 (1%)	81 (96%)	2 (2%)	0	82 (100%)	0	1 (1%)	79 (99%)	0	0.500
CREATINE KINASE	8 (10%)	64 (76%)	12 (14%)	6 (7%)	71 (87%)	5 (6%)	7 (9%)	65 (81%)	8 (10%)	0.474
CHLORIDE	3 (4%)	78 (93%)	3 (4%)	0	80 (98%)	2 (2%)	2 (3%)	77 (96%)	1 (1%)	0.496
CREATININE	0	82 (98%)	2 (2%)	0	81 (99%)	1 (1%)	0	80 (100%)	0	0.775
GAMMA GLUTAMYL TRANSFERASE	1 (1%)	81 (96%)	2 (2%)	4 (5%)	72 (88%)	6 (7%)	2 (3%)	74 (93%)	4 (5%)	0.378
GLUCOSE	1 (1%)	81 (96%)	2 (2%)	1 (1%)	81 (99%)	0	3 (4%)	74 (93%)	3 (4%)	0.317
POTASSIUM	2 (2%)	82 (98%)	0	2 (2%)	78 (96%)	1 (1%)	3 (4%)	74 (93%)	3 (4%)	0.464
SODIUM	10 (12%)	60 (71%)	14 (17%)	7 (9%)	62 (76%)	13 (16%)	12 (15%)	58 (73%)	10 (13%)	0.728
PHOSPHATE	1 (1%)	82 (98%)	1 (1%)	0	79 (98%)	2 (2%)	2 (3%)	76 (95%)	2 (3%)	0.661
PROTEIN	5 (6%)	73 (87%)	6 (7%)	1 (1%)	80 (98%)	1 (1%)	5 (6%)	74 (93%)	1 (1%)	0.062
URATE	2 (2%)	81 (96%)	1 (1%)	0	82 (100%)	0	0	80 (100%)	0	0.331

Note: Percentages are based on the number of subjects with non-missing assessments (i.e., the total of the subjects in the low, normal, and high categories) within each treatment group.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labnormfreq.sas

21:05 Monday, June 26, 2006

Table 14-6.03

Frequency of Normal and Abnormal (Clinically Significant Change from Previous Visit) Laboratory Values During Treatment

	Placebo (N=86)			Xan. Low (N=84)			Xan. High (N=84)			p-val [1]
	Low	Normal	High	Low	Normal	High	Low	Normal	High	
HEMATOLOGY										

BASOPHILS	1 (1%)	82 (98%)	1 (1%)	2 (2%)	80 (98%)	0	1 (1%)	79 (99%)	0	0.948
EOSINOPHILS	4 (5%)	80 (95%)	0	3 (4%)	70 (85%)	9 (11%)	4 (5%)	68 (85%)	8 (10%)	0.010
HEMATOCRIT	2 (2%)	79 (95%)	2 (2%)	4 (5%)	77 (95%)	0	1 (1%)	76 (95%)	3 (4%)	0.351
HEMOGLOBIN	0	84 (100%)	0	2 (2%)	80 (98%)	0	0	80 (100%)	0	0.215
LYMPHOCYTES	4 (5%)	76 (90%)	4 (5%)	2 (2%)	79 (96%)	1 (1%)	2 (3%)	77 (96%)	1 (1%)	0.498
ERY. MEAN	1 (1%)	83 (99%)	0	0	81 (99%)	1 (1%)	0	80 (100%)	0	0.884
CORPUSCULAR										
HEMOGLOBIN										
ERY. MEAN	1 (1%)	82 (99%)	0	0	80 (99%)	1 (1%)	0	80 (100%)	0	0.885
CORPUSCULAR HB										
CONCENTRATION										
ERY. MEAN	0	80 (96%)	3 (4%)	2 (2%)	78 (96%)	1 (1%)	1 (1%)	75 (94%)	4 (5%)	0.396
CORPUSCULAR VOLUME										
MONOCYTES	5 (6%)	74 (88%)	5 (6%)	1 (1%)	80 (98%)	1 (1%)	1 (1%)	78 (98%)	1 (1%)	0.081
PLATELET	0	84 (100%)	0	1 (1%)	80 (98%)	1 (1%)	0	79 (99%)	1 (1%)	0.546
ERYTHROCYTES	0	83 (99%)	1 (1%)	1 (1%)	81 (99%)	0	0	80 (100%)	0	0.884
LEUKOCYTES	4 (5%)	78 (93%)	2 (2%)	2 (2%)	77 (94%)	3 (4%)	3 (4%)	74 (93%)	3 (4%)	0.934

Note: Percentages are based on the number of subjects with non-missing assessments (i.e., the total of the subjects in the low, normal, and high categories) within each treatment group.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labnormfreq.sas

21:05 Monday, June 26, 2006

Protocol: CDISCPILOT01

Page 1 of 33

Population: Safety

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
CHEMISTRY								

ALANINE AMINOTRANSFERASE	2	n	81	2	77	1	78	0
		Normal	81 (100%)	0	77 (100%)	0	78 (100%)	0
		High	0	2 (100%)	0	1 (100%)	0	0
	4	n	77	2	69	1	72	0
		Normal	77 (100%)	1 (50%)	69 (100%)	0	72 (100%)	0
		High	0	1 (50%)	0	1 (100%)	0	0
	6	n	72	1	59	1	66	0
		Normal	71 (99%)	1 (100%)	59 (100%)	0	66 (100%)	0
		High	1 (1%)	0	0	1 (100%)	0	0
	8	n	71	1	57	1	56	0
		Normal	71 (100%)	0	57 (100%)	0	54 (96%)	0
		High	0	1 (100%)	0	1 (100%)	2 (4%)	0
	12	n	66	1	49	1	50	0
		Normal	65 (98%)	1 (100%)	48 (98%)	1 (100%)	49 (98%)	0
		High	1 (2%)	0	1 (2%)	0	1 (2%)	0
	16	n	67	1	40	0	37	0
		Normal	67 (100%)	1 (100%)	40 (100%)	0	37 (100%)	0
	20	n	64	1	29	0	31	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
	Normal	64 (100%)	1 (100%)	29 (100%)	0	31 (100%)	0
24	n	56	1	25	0	30	0
	Normal	55 (98%)	1 (100%)	25 (100%)	0	30 (100%)	0
	High	1 (2%)	0	0	0	0	0
26	n	56	1	24	0	27	0
	Normal	56 (100%)	1 (100%)	23 (96%)	0	27 (100%)	0
	High	0	0	1 (4%)	0	0	0
ALBUMIN	2	83	0	78	0	78	0
	Normal	83 (100%)	0	78 (100%)	0	78 (100%)	0
4	n	79	0	70	0	72	0
	Normal	79 (100%)	0	70 (100%)	0	72 (100%)	0
6	n	73	0	60	0	66	0
	Normal	73 (100%)	0	60 (100%)	0	66 (100%)	0
8	n	72	0	58	0	56	0
	Normal	72 (100%)	0	58 (100%)	0	56 (100%)	0
12	n	67	0	50	0	50	0
	Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
16	n	68	0	40	0	37	0
	Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
ALKALINE PHOSPHATASE	20	n	65	0	29	0	31	0
		Normal	65 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	25	0	30	0
		Normal	57 (100%)	0	25 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0
	2	n	82	2	78	0	77	1
		Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0
		High	0	2 (100%)	0	0	0	1 (100%)
	4	n	80	2	69	0	71	1
		Normal	80 (100%)	0	69 (100%)	0	71 (100%)	0
		High	0	2 (100%)	0	0	0	1 (100%)
6	n	75	0	62	0	66	1	
	Normal	75 (100%)	0	62 (100%)	0	66 (100%)	0	
	High	0	0	0	0	0	1 (100%)	
8	n	72	1	58	0	55	1	
	Normal	72 (100%)	0	57 (98%)	0	55 (100%)	0	
	High	0	1 (100%)	1 (2%)	0	0	1 (100%)	
12	n	66	1	50	0	49	1	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
	Normal	66 (100%)	0	50 (100%)	0	49 (100%)	0	
	High	0	1 (100%)	0	0	0	1 (100%)	
16	n	67	1	40	0	36	1	
	Normal	67 (100%)	0	40 (100%)	0	36 (100%)	0	
	High	0	1 (100%)	0	0	0	1 (100%)	
20	n	64	1	30	0	30	1	
	Normal	63 (98%)	0	30 (100%)	0	30 (100%)	0	
	High	1 (2%)	1 (100%)	0	0	0	1 (100%)	
24	n	55	1	26	0	30	0	
	Normal	54 (98%)	0	26 (100%)	0	30 (100%)	0	
	High	1 (2%)	1 (100%)	0	0	0	0	
26	n	56	1	24	0	27	0	
	Normal	55 (98%)	0	24 (100%)	0	27 (100%)	0	
	High	1 (2%)	1 (100%)	0	0	0	0	
ASPARTATE AMINOTRANSFERASE	2	n	81	2	78	0	78	0
		Normal	80 (99%)	1 (50%)	77 (99%)	0	78 (100%)	0
		High	1 (1%)	1 (50%)	1 (1%)	0	0	0
	4	n	77	2	69	1	72	0
		Normal	76 (99%)	1 (50%)	69 (100%)	1 (100%)	72 (100%)	0
		High	1 (1%)	1 (50%)	0	0	0	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

Week	Shift to	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
6	n	72	1	60	0	66	0
	Normal	71 (99%)	1 (100%)	60 (100%)	0	65 (98%)	0
	High	1 (1%)	0	0	0	1 (2%)	0
8	n	71	1	58	0	56	0
	Normal	70 (99%)	1 (100%)	58 (100%)	0	55 (98%)	0
	High	1 (1%)	0	0	0	1 (2%)	0
12	n	66	1	50	0	50	0
	Normal	65 (98%)	1 (100%)	49 (98%)	0	50 (100%)	0
	High	1 (2%)	0	1 (2%)	0	0	0
16	n	67	1	40	0	37	0
	Normal	67 (100%)	1 (100%)	39 (98%)	0	37 (100%)	0
	High	0	0	1 (3%)	0	0	0
20	n	64	1	29	0	31	0
	Normal	64 (100%)	1 (100%)	29 (100%)	0	31 (100%)	0
24	n	56	1	25	0	30	0
	Normal	54 (96%)	1 (100%)	24 (96%)	0	30 (100%)	0
	High	2 (4%)	0	1 (4%)	0	0	0
26	n	56	1	24	0	27	0
	Normal	55 (98%)	1 (100%)	23 (96%)	0	27 (100%)	0
	High	1 (2%)	0	1 (4%)	0	0	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
BILIRUBIN	2	n	83	0	78	0	77	1
		Normal	82 (99%)	0	78 (100%)	0	77 (100%)	1 (100%)
		High	1 (1%)	0	0	0	0	0
	4	n	79	0	70	0	71	1
		Normal	78 (99%)	0	70 (100%)	0	71 (100%)	0
		High	1 (1%)	0	0	0	0	1 (100%)
	6	n	73	0	60	0	65	1
		Normal	73 (100%)	0	60 (100%)	0	65 (100%)	1 (100%)
	8	n	72	0	58	0	55	1
		Normal	72 (100%)	0	58 (100%)	0	55 (100%)	1 (100%)
	12	n	67	0	50	0	49	1
		Normal	67 (100%)	0	50 (100%)	0	48 (98%)	1 (100%)
		High	0	0	0	0	1 (2%)	0
	16	n	68	0	40	0	36	1
		Normal	68 (100%)	0	40 (100%)	0	36 (100%)	1 (100%)
	20	n	65	0	29	0	30	1
		Normal	65 (100%)	0	29 (100%)	0	29 (97%)	1 (100%)
		High	0	0	0	0	1 (3%)	0
	24	n	57	0	25	0	29	1

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
	Normal	57 (100%)	0	25 (100%)	0	29 (100%)	1 (100%)
CALCIUM	26 n	57	0	24	0	26	1
	Normal	57 (100%)	0	23 (96%)	0	26 (100%)	1 (100%)
	High	0	0	1 (4%)	0	0	0
	2 n	84	0	78	0	78	0
	Normal	84 (100%)	0	78 (100%)	0	78 (100%)	0
	4 n	82	0	70	0	72	0
	Normal	82 (100%)	0	70 (100%)	0	72 (100%)	0
	6 n	75	0	62	0	67	0
	Normal	75 (100%)	0	62 (100%)	0	67 (100%)	0
	8 n	73	0	58	0	56	0
	Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12 n	67	0	50	0	50	0
	Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
	16 n	68	0	40	0	37	0
	Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20 n	66	0	30	0	31	0
	Normal	66 (100%)	0	30 (100%)	0	31 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
CHLORIDE	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0
	2	n	84	0	78	0	76	0
		Normal	84 (100%)	0	78 (100%)	0	76 (100%)	0
	4	n	82	0	70	0	71	0
		Normal	82 (100%)	0	70 (100%)	0	71 (100%)	0
	6	n	75	0	62	0	66	0
		Normal	75 (100%)	0	62 (100%)	0	66 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	49	0
		Normal	67 (100%)	0	50 (100%)	0	49 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	65	0	30	0	31	0
		Normal	65 (100%)	0	30 (100%)	0	31 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
CHOLESTEROL	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0
	2	n	84	0	78	0	78	0
		Normal	84 (100%)	0	78 (100%)	0	78 (100%)	0
	4	n	82	0	70	0	72	0
		Normal	82 (100%)	0	70 (100%)	0	72 (100%)	0
	6	n	75	0	62	0	67	0
		Normal	75 (100%)	0	62 (100%)	0	67 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	50	0
		Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	66	0	30	0	31	0
		Normal	66 (100%)	0	30 (100%)	0	31 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
CREATINE KINASE	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0
	2	n	83	0	77	1	75	3
		Normal	81 (98%)	0	74 (96%)	1 (100%)	74 (99%)	3 (100%)
		High	2 (2%)	0	3 (4%)	0	1 (1%)	0
	4	n	79	0	69	1	69	3
		Normal	78 (99%)	0	68 (99%)	1 (100%)	68 (99%)	3 (100%)
		High	1 (1%)	0	1 (1%)	0	1 (1%)	0
	6	n	73	0	59	1	63	3
		Normal	73 (100%)	0	58 (98%)	1 (100%)	61 (97%)	2 (67%)
		High	0	0	1 (2%)	0	2 (3%)	1 (33%)
	8	n	72	0	57	1	54	2
		Normal	71 (99%)	0	57 (100%)	1 (100%)	53 (98%)	2 (100%)
		High	1 (1%)	0	0	0	1 (2%)	0
12	n	67	0	49	1	48	2	
	Normal	65 (97%)	0	48 (98%)	1 (100%)	47 (98%)	1 (50%)	
	High	2 (3%)	0	1 (2%)	0	1 (2%)	1 (50%)	
16	n	68	0	39	1	36	1	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
CREATININE	Normal	66 (97%)	0	39 (100%)	1 (100%)	36 (100%)	1 (100%)
	High	2 (3%)	0	0	0	0	0
	20 n	65	0	29	0	30	1
	Normal	65 (100%)	0	27 (93%)	0	29 (97%)	1 (100%)
	High	0	0	2 (7%)	0	1 (3%)	0
	24 n	57	0	25	0	29	1
	Normal	55 (96%)	0	25 (100%)	0	29 (100%)	1 (100%)
	High	2 (4%)	0	0	0	0	0
	26 n	57	0	24	0	26	1
	Normal	57 (100%)	0	24 (100%)	0	25 (96%)	1 (100%)
	High	0	0	0	0	1 (4%)	0
	2 n	84	0	78	0	78	0
	Normal	84 (100%)	0	78 (100%)	0	78 (100%)	0
	4 n	82	0	70	0	72	0
	Normal	82 (100%)	0	70 (100%)	0	72 (100%)	0
	6 n	75	0	62	0	67	0
Normal	75 (100%)	0	62 (100%)	0	67 (100%)	0	
8 n	73	0	58	0	56	0	
Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.
There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
GAMMA GLUTAMYL TRANSFERASE	12	n	67	0	50	0	50	0
		Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	66	0	30	0	31	0
		Normal	66 (100%)	0	30 (100%)	0	31 (100%)	0
	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0
	2	n	82	2	76	2	76	2
		Normal	82 (100%)	1 (50%)	75 (99%)	1 (50%)	75 (99%)	1 (50%)
		High	0	1 (50%)	1 (1%)	1 (50%)	1 (1%)	1 (50%)
	4	n	80	2	68	2	70	2
		Normal	80 (100%)	1 (50%)	68 (100%)	1 (50%)	70 (100%)	1 (50%)
		High	0	1 (50%)	0	1 (50%)	0	1 (50%)
	6	n	74	1	61	1	66	1
		Normal	74 (100%)	0	61 (100%)	1 (100%)	66 (100%)	0
	High	0	1 (100%)	0	0	0	1 (100%)	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
8	n	72	1	57	1	55	1
	Normal	72 (100%)	0	56 (98%)	1 (100%)	54 (98%)	0
	High	0	1 (100%)	1 (2%)	0	1 (2%)	1 (100%)
12	n	66	1	49	1	49	1
	Normal	66 (100%)	0	49 (100%)	1 (100%)	49 (100%)	0
	High	0	1 (100%)	0	0	0	1 (100%)
16	n	67	1	39	1	36	1
	Normal	67 (100%)	1 (100%)	39 (100%)	1 (100%)	36 (100%)	0
	High	0	0	0	0	0	1 (100%)
20	n	65	1	29	1	31	0
	Normal	65 (100%)	0	29 (100%)	0	31 (100%)	0
	High	0	1 (100%)	0	1 (100%)	0	0
24	n	56	1	26	0	29	1
	Normal	54 (96%)	1 (100%)	25 (96%)	0	29 (100%)	0
	High	2 (4%)	0	1 (4%)	0	0	1 (100%)
26	n	56	1	24	0	26	1
	Normal	55 (98%)	1 (100%)	23 (96%)	0	26 (100%)	0
	High	1 (2%)	0	1 (4%)	0	0	1 (100%)
GLUCOSE	2 n	82	1	78	0	78	0
	Normal	82 (100%)	1 (100%)	78 (100%)	0	77 (99%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

Week	Shift to	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
	High	0	0	0	0	1 (1%)	0
4	n	78	1	69	0	72	0
	Normal	78 (100%)	1 (100%)	69 (100%)	0	72 (100%)	0
6	n	72	1	60	0	66	0
	Normal	72 (100%)	1 (100%)	60 (100%)	0	65 (98%)	0
	High	0	0	0	0	1 (2%)	0
8	n	71	1	57	0	56	0
	Normal	71 (100%)	1 (100%)	57 (100%)	0	56 (100%)	0
12	n	66	1	50	0	49	0
	Normal	66 (100%)	1 (100%)	49 (98%)	0	49 (100%)	0
	High	0	0	1 (2%)	0	0	0
16	n	67	1	40	0	37	0
	Normal	67 (100%)	1 (100%)	40 (100%)	0	37 (100%)	0
20	n	64	1	29	0	31	0
	Normal	64 (100%)	1 (100%)	29 (100%)	0	31 (100%)	0
24	n	56	1	25	0	30	0
	Normal	56 (100%)	1 (100%)	25 (100%)	0	30 (100%)	0
26	n	56	1	24	0	27	0
	Normal	56 (100%)	1 (100%)	24 (100%)	0	27 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
PHOSPHATE	2	n	84	0	78	0	78	0
		Normal	84 (100%)	0	78 (100%)	0	78 (100%)	0
	4	n	82	0	68	0	72	0
		Normal	82 (100%)	0	68 (100%)	0	72 (100%)	0
	6	n	75	0	62	0	67	0
		Normal	75 (100%)	0	62 (100%)	0	67 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	50	0
		Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	65	0	30	0	31	0
		Normal	65 (100%)	0	30 (100%)	0	31 (100%)	0
	24	n	56	0	26	0	30	0
		Normal	56 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
POTASSIUM	2	n	84	0	78	0	76	0
		Normal	84 (100%)	0	78 (100%)	0	76 (100%)	0
	4	n	82	0	68	0	71	0
		Normal	82 (100%)	0	68 (100%)	0	71 (100%)	0
	6	n	75	0	62	0	66	0
		Normal	75 (100%)	0	62 (100%)	0	66 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	49	0
		Normal	67 (100%)	0	50 (100%)	0	49 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	64	0	30	0	31	0
		Normal	64 (100%)	0	30 (100%)	0	31 (100%)	0
	24	n	56	0	26	0	30	0
		Normal	56 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
PROTEIN	2	n	84	0	78	0	78	0
		Normal	84 (100%)	0	78 (100%)	0	78 (100%)	0
	4	n	82	0	70	0	72	0
		Normal	82 (100%)	0	70 (100%)	0	72 (100%)	0
	6	n	75	0	62	0	67	0
		Normal	75 (100%)	0	62 (100%)	0	67 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	50	0
		Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	66	0	30	0	31	0
		Normal	66 (100%)	0	30 (100%)	0	31 (100%)	0
	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
SODIUM	2	n	84	0	78	0	76	0
		Normal	84 (100%)	0	78 (100%)	0	76 (100%)	0
	4	n	82	0	70	0	71	0
		Normal	82 (100%)	0	70 (100%)	0	71 (100%)	0
	6	n	75	0	62	0	66	0
		Normal	75 (100%)	0	62 (100%)	0	66 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	49	0
		Normal	67 (100%)	0	50 (100%)	0	49 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	65	0	30	0	31	0
		Normal	65 (100%)	0	30 (100%)	0	31 (100%)	0
	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
URATE	2	n	84	0	78	0	78	0
		Normal	84 (100%)	0	78 (100%)	0	78 (100%)	0
	4	n	82	0	70	0	72	0
		Normal	82 (100%)	0	70 (100%)	0	72 (100%)	0
	6	n	75	0	62	0	67	0
		Normal	75 (100%)	0	62 (100%)	0	67 (100%)	0
	8	n	73	0	58	0	56	0
		Normal	73 (100%)	0	58 (100%)	0	56 (100%)	0
	12	n	67	0	50	0	50	0
		Normal	67 (100%)	0	50 (100%)	0	50 (100%)	0
	16	n	68	0	40	0	37	0
		Normal	68 (100%)	0	40 (100%)	0	37 (100%)	0
	20	n	66	0	30	0	31	0
		Normal	66 (100%)	0	30 (100%)	0	31 (100%)	0
	24	n	57	0	26	0	30	0
		Normal	57 (100%)	0	26 (100%)	0	30 (100%)	0
	26	n	57	0	24	0	27	0
		Normal	57 (100%)	0	24 (100%)	0	27 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
			Normal at	High at	Normal at	High at	Normal at	High at
			Baseline	Baseline	Baseline	Baseline	Baseline	Baseline
Week	Shift to							
UREA NITROGEN	2	n	84	0	76	2	78	0
		Normal	84 (100%)	0	76 (100%)	2 (100%)	77 (99%)	0
		High	0	0	0	0	1 (1%)	0
	4	n	82	0	68	2	72	0
		Normal	82 (100%)	0	68 (100%)	2 (100%)	72 (100%)	0
	6	n	75	0	60	2	67	0
		Normal	75 (100%)	0	60 (100%)	2 (100%)	67 (100%)	0
	8	n	73	0	56	2	56	0
		Normal	73 (100%)	0	56 (100%)	2 (100%)	56 (100%)	0
	12	n	67	0	49	1	50	0
		Normal	67 (100%)	0	49 (100%)	1 (100%)	50 (100%)	0
	16	n	68	0	39	1	37	0
		Normal	68 (100%)	0	39 (100%)	1 (100%)	37 (100%)	0
	20	n	66	0	29	1	31	0
		Normal	66 (100%)	0	29 (100%)	1 (100%)	31 (100%)	0
	24	n	57	0	25	1	30	0
		Normal	57 (100%)	0	25 (100%)	1 (100%)	30 (100%)	0
	26	n	57	0	23	1	27	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
	Normal	57 (100%)	0	23 (100%)	1 (100%)	26 (96%)	0
	High	0	0	0	0	1 (4%)	0
HEMATOLOGY							

BASOPHILS							
2	n	82	0	77	0	77	0
	Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
4	n	78	0	69	0	69	0
	Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
6	n	72	0	59	0	62	0
	Normal	72 (100%)	0	59 (100%)	0	62 (100%)	0
8	n	71	0	56	0	55	0
	Normal	71 (100%)	0	56 (100%)	0	55 (100%)	0
12	n	65	0	48	0	49	0
	Normal	65 (100%)	0	48 (100%)	0	49 (100%)	0
16	n	67	0	39	0	36	0
	Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
20	n	64	0	29	0	31	0
	Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
EOSINOPHILS	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	56	0	24	0	26	0
		Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	76	1	77	0
		Normal	82 (100%)	0	74 (97%)	1 (100%)	77 (100%)	0
		High	0	0	2 (3%)	0	0	0
	4	n	78	0	69	0	69	0
		Normal	78 (100%)	0	69 (100%)	0	68 (99%)	0
		High	0	0	0	0	1 (1%)	0
	6	n	72	0	59	0	62	0
		Normal	72 (100%)	0	59 (100%)	0	58 (94%)	0
		High	0	0	0	0	4 (6%)	0
	8	n	71	0	56	0	55	0
		Normal	71 (100%)	0	53 (95%)	0	52 (95%)	0
		High	0	0	3 (5%)	0	3 (5%)	0
12	n	65	0	48	0	49	0	
	Normal	65 (100%)	0	46 (96%)	0	49 (100%)	0	
	High	0	0	2 (4%)	0	0	0	
16	n	67	0	39	0	36	0	

NOTES: Only subjects with baseline results are included in the summary.
There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
ERY. MEAN CORPUSCULAR HB CONCENTRATION		Normal	67 (100%)	0	39 (100%)	0	35 (97%)	0
		High	0	0	0	0	1 (3%)	0
	20	n	64	0	29	0	31	0
		Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	56	0	24	0	26	0
		Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	76	0	76	0
		Normal	82 (100%)	0	76 (100%)	0	76 (100%)	0
	4	n	76	0	67	0	67	0
		Normal	76 (100%)	0	67 (100%)	0	67 (100%)	0
	6	n	71	0	57	0	63	0
		Normal	71 (100%)	0	57 (100%)	0	63 (100%)	0
	8	n	70	0	53	0	55	0
		Normal	70 (100%)	0	53 (100%)	0	55 (100%)	0
12	n	64	0	47	0	49	0	
	Normal	64 (100%)	0	47 (100%)	0	49 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
ERY. MEAN CORPUSCULAR HEMOGLOBIN	16 n	67	0	39	0	36	0
	Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20 n	63	0	29	0	31	0
	Normal	63 (100%)	0	29 (100%)	0	31 (100%)	0
	24 n	57	0	24	0	29	0
	Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26 n	55	0	24	0	26	0
	Normal	55 (100%)	0	24 (100%)	0	26 (100%)	0
	2 n	82	0	77	0	77	0
	Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
	4 n	78	0	69	0	69	0
	Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
	6 n	72	0	59	0	63	0
	Normal	72 (100%)	0	59 (100%)	0	63 (100%)	0
	8 n	71	0	56	0	55	0
	Normal	71 (100%)	0	56 (100%)	0	55 (100%)	0
	12 n	65	0	48	0	49	0

NOTES: Only subjects with baseline results are included in the summary.
There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
ERY. MEAN CORPUSCULAR VOLUME		Normal	65 (100%)	0	48 (100%)	0	49 (100%)	0
	16	n	67	0	39	0	36	0
		Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20	n	64	0	29	0	31	0
		Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	56	0	24	0	26	0
		Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	76	0	76	0
		Normal	82 (100%)	0	76 (100%)	0	76 (100%)	0
	4	n	76	0	67	0	67	0
		Normal	76 (100%)	0	67 (100%)	0	67 (100%)	0
	6	n	71	0	57	0	63	0
		Normal	71 (100%)	0	57 (100%)	0	63 (100%)	0
	8	n	70	0	53	0	55	0
Normal		70 (100%)	0	53 (100%)	0	55 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
ERYTHROCYTES	12	n	64	0	47	0	49	0
		Normal	64 (100%)	0	47 (100%)	0	49 (100%)	0
	16	n	67	0	39	0	36	0
		Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20	n	63	0	29	0	31	0
		Normal	63 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	55	0	24	0	26	0
		Normal	55 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	77	0	77	0
		Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
	4	n	78	0	69	0	69	0
		Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
	6	n	72	0	59	0	63	0
		Normal	72 (100%)	0	59 (100%)	0	63 (100%)	0
	8	n	71	0	56	0	55	0
		Normal	71 (100%)	0	56 (100%)	0	55 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
HEMATOCRIT	12	n	65	0	48	0	49	0
		Normal	65 (100%)	0	48 (100%)	0	49 (100%)	0
	16	n	67	0	39	0	36	0
		Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20	n	64	0	29	0	31	0
		Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	56	0	24	0	26	0
		Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	76	0	76	0
		Normal	82 (100%)	0	76 (100%)	0	76 (100%)	0
	4	n	76	0	67	0	67	0
		Normal	76 (100%)	0	67 (100%)	0	67 (100%)	0
	6	n	71	0	57	0	63	0
		Normal	71 (100%)	0	57 (100%)	0	63 (100%)	0
	8	n	70	0	53	0	55	0
		Normal	70 (100%)	0	53 (100%)	0	55 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
HEMOGLOBIN	12	n	64	0	47	0	49	0
		Normal	64 (100%)	0	47 (100%)	0	49 (100%)	0
	16	n	67	0	39	0	36	0
		Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20	n	63	0	29	0	31	0
		Normal	63 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	55	0	24	0	26	0
		Normal	55 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	77	0	77	0
		Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
	4	n	78	0	69	0	69	0
		Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
	6	n	72	0	59	0	63	0
		Normal	72 (100%)	0	59 (100%)	0	63 (100%)	0
	8	n	71	0	56	0	55	0
		Normal	71 (100%)	0	56 (100%)	0	55 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
LEUKOCYTES	12	n	65	0	48	0	49	0
		Normal	65 (100%)	0	48 (100%)	0	49 (100%)	0
	16	n	67	0	39	0	36	0
		Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20	n	64	0	29	0	31	0
		Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	56	0	24	0	26	0
		Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	77	0	77	0
		Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
	4	n	78	0	69	0	69	0
		Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
	6	n	72	0	59	0	63	0
		Normal	72 (100%)	0	59 (100%)	0	63 (100%)	0
	8	n	71	0	56	0	55	0
		Normal	71 (100%)	0	56 (100%)	0	55 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

			Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
	Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
LYMPHOCYTES	12	n	65	0	48	0	49	0
		Normal	65 (100%)	0	48 (100%)	0	49 (100%)	0
	16	n	67	0	39	0	36	0
		Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20	n	64	0	29	0	31	0
		Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
	24	n	57	0	24	0	29	0
		Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26	n	56	0	24	0	26	0
		Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2	n	82	0	77	0	77	0
		Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
	4	n	78	0	69	0	69	0
		Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
	6	n	72	0	59	0	62	0
		Normal	72 (100%)	0	59 (100%)	0	62 (100%)	0
	8	n	71	0	56	0	55	0
		Normal	70 (99%)	0	56 (100%)	0	55 (100%)	0
		High	1 (1%)	0	0	0	0	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04
Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
MONOCYTES	12 n	65	0	48	0	49	0
	Normal	64 (98%)	0	48 (100%)	0	49 (100%)	0
	High	1 (2%)	0	0	0	0	0
	16 n	67	0	39	0	36	0
	Normal	67 (100%)	0	39 (100%)	0	36 (100%)	0
	20 n	64	0	29	0	31	0
	Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
	24 n	57	0	24	0	29	0
	Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
	26 n	56	0	24	0	26	0
	Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
	2 n	82	0	77	0	77	0
	Normal	82 (100%)	0	77 (100%)	0	77 (100%)	0
	4 n	78	0	69	0	69	0
	Normal	78 (100%)	0	69 (100%)	0	69 (100%)	0
	6 n	72	0	59	0	62	0
	Normal	71 (99%)	0	59 (100%)	0	62 (100%)	0
	Low	1 (1%)	0	0	0	0	0

NOTES: Only subjects with baseline results are included in the summary.
There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
Week	Shift to	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
8	n	71	0	56	0	55	0
	Normal	71 (100%)	0	56 (100%)	0	55 (100%)	0
12	n	65	0	48	0	49	0
	Normal	65 (100%)	0	48 (100%)	0	49 (100%)	0
16	n	67	0	39	0	36	0
	Normal	66 (99%)	0	39 (100%)	0	36 (100%)	0
	Low	1 (1%)	0	0	0	0	0
20	n	64	0	29	0	31	0
	Normal	64 (100%)	0	29 (100%)	0	31 (100%)	0
24	n	57	0	24	0	29	0
	Normal	57 (100%)	0	24 (100%)	0	29 (100%)	0
26	n	56	0	24	0	26	0
	Normal	56 (100%)	0	24 (100%)	0	26 (100%)	0
PLATELET	n	82	0	74	0	77	0
	Normal	82 (100%)	0	74 (100%)	0	77 (100%)	0
4	n	77	0	67	0	68	0
	Normal	77 (100%)	0	67 (100%)	0	68 (100%)	0
6	n	72	0	57	0	61	0
	Normal	72 (100%)	0	57 (100%)	0	61 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.04

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges, by Visit

Week	Shift to	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)	
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline
8	n	71	0	55	0	54	0
	Normal	71 (100%)	0	55 (100%)	0	54 (100%)	0
12	n	64	0	47	0	48	0
	Normal	64 (100%)	0	47 (100%)	0	48 (100%)	0
16	n	67	0	37	0	36	0
	Normal	67 (100%)	0	37 (100%)	0	36 (100%)	0
20	n	64	0	28	0	30	0
	Normal	64 (100%)	0	28 (100%)	0	30 (100%)	0
24	n	56	0	22	0	28	0
	Normal	56 (100%)	0	22 (100%)	0	28 (100%)	0
26	n	55	0	23	0	26	0
	Normal	55 (100%)	0	23 (100%)	0	26 (100%)	0

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshiftweek.sas

21:05 Monday, June 26, 2006

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)			
		Shift	Normal at	High at	Normal at	High at	Normal at	High at	p-
		[1]	Baseline	Baseline	Baseline	Baseline	Baseline	Baseline	value
									[2]
CHEMISTRY									

ALANINE AMINOTRANSFERASE	n		82	2	79	1	80	0	0.828
	Normal		80 (98%)	0	78 (99%)	0	78 (98%)	0	
	High		2 (2%)	2 (100%)	1 (1%)	1 (100%)	2 (3%)	0	
ALBUMIN	n		84	0	80	0	80	0	
	Normal		84 (100%)	0	80 (100%)	0	80 (100%)	0	
ALKALINE PHOSPHATASE	n		82	2	79	0	79	1	0.611
	Normal		81 (99%)	0	78 (99%)	0	79 (100%)	0	
	High		1 (1%)	2 (100%)	1 (1%)	0	0	1 (100%)	
ASPARTATE AMINOTRANSFERASE	n		82	2	79	1	80	0	0.770
	Normal		79 (96%)	1 (50%)	77 (97%)	1 (100%)	78 (98%)	0	
	High		3 (4%)	1 (50%)	2 (3%)	0	2 (3%)	0	
BILIRUBIN	n		84	0	80	0	79	1	0.353
	Normal		83 (99%)	0	80 (100%)	0	77 (97%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p- value [2]
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
	High	1 (1%)	0	0	0	2 (3%)	1 (100%)	
CALCIUM	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
CHLORIDE	n	84	0	80	0	79	0	
	Normal	84 (100%)	0	80 (100%)	0	79 (100%)	0	
CHOLESTEROL	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
CREATINE KINASE	n	84	0	79	1	77	3	0.811
	Normal	77 (92%)	0	74 (94%)	1 (100%)	72 (94%)	1 (33%)	
	High	7 (8%)	0	5 (6%)	0	5 (6%)	2 (67%)	
CREATININE	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
GAMMA GLUTAMYL TRANSFERASE	n	82	2	78	2	78	2	0.898
	Normal	80 (98%)	0	75 (96%)	1 (50%)	76 (97%)	1 (50%)	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value [2]
	Shift [1]	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
	High	2 (2%)	2 (100%)	3 (4%)	1 (50%)	2 (3%)	1 (50%)	
GLUCOSE	n	83	1	80	0	80	0	0.354
	Normal	83 (100%)	1 (100%)	79 (99%)	0	78 (98%)	0	
	High	0	0	1 (1%)	0	2 (3%)	0	
PHOSPHATE	n	84	0	79	0	80	0	
	Normal	84 (100%)	0	79 (100%)	0	80 (100%)	0	
POTASSIUM	n	84	0	79	0	79	0	
	Normal	84 (100%)	0	79 (100%)	0	79 (100%)	0	
PROTEIN	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	
SODIUM	n	84	0	80	0	79	0	
	Normal	84 (100%)	0	80 (100%)	0	79 (100%)	0	
URATE	n	84	0	80	0	80	0	
	Normal	84 (100%)	0	80 (100%)	0	80 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		
	Shift [1]	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	p-value [2]
UREA NITROGEN	n	84	0	78	2	80	0	0.363
	Normal	84 (100%)	0	78 (100%)	2 (100%)	79 (99%)	0	
	High	0	0	0	0	1 (1%)	0	
HEMATOLOGY								

BASOPHILS	n	83	0	79	0	78	0	0.044
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
EOSINOPHILS	n	83	0	78	1	78	0	
	Normal	83 (100%)	0	73 (94%)	1 (100%)	72 (92%)	0	
	High	0	0	5 (6%)	0	6 (8%)	0	
ERY. MEAN CORPUSCULAR HBn CONCENTRATION	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
ERY. MEAN CORPUSCULAR HEMOGLOBIN	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value [2]
	Shift [1]	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
ERY. MEAN CORPUSCULAR VOLUME	n	82	0	78	0	77	0	0.388
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
ERYTHROCYTES	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
HEMATOCRIT	n	82	0	78	0	77	0	
	Normal	82 (100%)	0	78 (100%)	0	77 (100%)	0	
HEMOGLOBIN	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
LEUKOCYTES	n	83	0	79	0	78	0	
	Normal	83 (100%)	0	79 (100%)	0	78 (100%)	0	
LYMPHOCYTES	n	83	0	79	0	78	0	
	Normal	82 (99%)	0	79 (100%)	0	78 (100%)	0	
	High	1 (1%)	0	0	0	0	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.05

Shifts of Laboratory Values During Treatment, Categorized Based on Threshold Ranges

	Shift [1]	Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p- value [2]
		Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	
MONOCYTES	n	83	0	79	0	78	0	0.150
	Normal	81 (98%)	0	79 (100%)	0	78 (100%)	0	
	Low	2 (2%)	0	0	0	0	0	
PLATELET	n	83	0	77	0	78	0	
	Normal	83 (100%)	0	77 (100%)	0	78 (100%)	0	

NOTES: Only subjects with baseline results are included in the summary.

There were no subjects with abnormal low values at baseline.

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_labshift.sas

21:05 Monday, June 26, 2006

Table 14-6.06
Shifts of Hy's Law Values During Treatment

		Placebo (N=86)		Xan. Low (N=84)		Xan. High (N=84)		p-value [2]
		Shift [1]	Normal at Baseline	High at Baseline	Normal at Baseline	High at Baseline	Normal at Baseline	
Transaminase 1.5 x ULN	n		82	2	80	2	80	0.392
	Normal		79 (96%)	0	79 (99%)	1 (50%)	77 (96%)	
	High		3 (4%)	2 (100%)	1 (1%)	1 (50%)	3 (4%)	
Total Bili 1.5 x ULN and								
Transaminase 1.5 x ULN	n		84	0	82	0	80	0.381
	Normal		83 (99%)	0	82 (100%)	0	80 (100%)	
	High		1 (1%)	0	0	0	0	

NOTES: Only subjects with baseline results are included in the summary.

The single subject with elevated transaminase and elevated bilirubin also had elevated alk phos (>3xULN).

[1] A subject is counted only once for each analyte. A change will be considered shifting from normal at baseline to abnormal or from abnormal at baseline to normal at any visit during the treatment. The treatment period is defined as any planned visit after Week 0 (Visit 3), up to and including Week 24 (Visit 12).

[2] CMH test for general association, controlling for status at baseline.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rt_hyslaw.sas

21:03 Monday, June 26, 2006

Protocol: CDISCPILOT01

Page 1 of 5

Population: Safety

Table 14-7.01
Summary of Vital Signs at Baseline and End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
Systolic Blood Pressure (mmHg)	AFTER LYING DOWN FOR 5 MINUTES	Placebo	86	Baseline	85	138.6	16.75	140.0	90.0	180.0
				Week 24	59	135.8	17.30	131.0	100.0	180.0
				End of Trt.	84	136.7	18.30	134.0	100.0	180.0
		Xan.Low	84	Baseline	84	138.8	16.55	138.0	100.0	178.0
				Week 24	27	134.1	16.74	136.0	100.0	173.0
				End of Trt.	84	135.7	17.17	134.0	100.0	190.0
	AFTER STANDING FOR 1 MINUTE	Placebo	86	Baseline	85	135.3	17.89	134.0	90.0	180.0
				Week 24	59	133.5	19.23	130.0	90.0	199.0
				End of Trt.	84	133.9	18.68	130.5	90.0	199.0
		Xan.Low	84	Baseline	84	135.6	18.04	136.0	100.0	186.0
				Week 24	27	131.0	17.82	130.0	92.0	168.0
				End of Trt.	84	132.8	17.53	130.0	92.0	180.0
	AFTER STANDING FOR 3 MINUTES	Placebo	86	Baseline	85	136.5	18.77	136.0	80.0	184.0
				Week 24	30	130.4	20.83	128.0	96.0	198.0
				End of Trt.	82	130.4	20.37	128.0	90.0	198.0
		Xan.High	84	Baseline	84	140.1	17.82	141.0	100.0	188.0
				Week 24	30	132.2	18.18	130.0	101.0	178.0
				End of Trt.	82	134.0	17.86	130.0	101.0	178.0

locf

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.01
Summary of Vital Signs at Baseline and End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
Diastolic Blood Pressure (mmHg)	AFTER LYING DOWN FOR 5 MINUTES	Placebo	86	Week 24	59	134.8	17.35	131.0	100.0	190.0
				End of Trt.	84	134.1	18.01	130.0	90.0	190.0
				Xan.Low	84	Baseline	84	136.4	18.11	134.5
				Week 24	27	131.0	17.92	130.0	100.0	168.0
				End of Trt.	83	133.1	17.80	130.0	98.0	200.0
				Xan.High	84	Baseline	84	138.8	18.75	138.0
				Week 24	30	129.2	16.95	126.0	90.0	172.0
				End of Trt.	81	130.4	17.77	130.0	88.0	184.0
		Placebo	86	Baseline	85	75.7	11.09	76.0	40.0	99.0
				Week 24	59	72.9	11.32	74.0	44.0	109.0
				End of Trt.	84	74.5	11.11	76.0	44.0	109.0
				Xan.Low	84	Baseline	84	76.3	9.77	76.0
				Week 24	27	76.1	9.14	76.0	60.0	90.0
				End of Trt.	84	74.3	8.88	74.0	45.0	90.0
				Xan.High	84	Baseline	84	77.2	9.80	78.0
				Week 24	30	73.9	9.23	74.0	60.0	92.0
				End of Trt.	82	74.1	9.27	74.0	56.0	94.0
	AFTER STANDING FOR 1 MINUTE	Placebo	86	Baseline	85	77.9	10.63	78.0	51.0	104.0
				Week 24	59	74.2	12.89	74.0	45.0	117.0
				End of Trt.	84	74.9	12.16	76.0	45.0	117.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.01
Summary of Vital Signs at Baseline and End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
Pulse (bpm)		Xan.Low	84	Baseline	84	76.2	10.14	78.0	54.0	98.0
				Week 24	27	76.3	10.28	78.0	60.0	98.0
				End of Trt.	84	75.0	9.34	75.0	51.0	98.0
		Xan.High	84	Baseline	84	78.1	10.77	78.0	56.0	108.0
				Week 24	30	74.9	11.00	76.0	50.0	97.0
				End of Trt.	82	75.9	11.77	76.5	48.0	112.0
		Placebo	86	Baseline	85	77.7	11.00	78.0	46.0	110.0
				Week 24	59	74.3	11.38	74.0	51.0	110.0
				End of Trt.	84	75.0	11.19	74.5	51.0	110.0
	AFTER STANDING FOR 3 MINUTES	Xan.Low	84	Baseline	84	76.6	10.93	76.0	48.0	108.0
				Week 24	27	76.2	10.18	76.0	57.0	98.0
				End of Trt.	83	74.9	9.66	74.0	57.0	102.0
		Xan.High	84	Baseline	84	79.6	10.19	80.0	51.0	104.0
				Week 24	30	76.0	10.63	78.5	50.0	98.0
				End of Trt.	81	76.8	11.71	78.0	50.0	118.0
	AFTER LYING DOWN FOR 5 MINUTES	Placebo	86	Baseline	85	70.4	10.46	70.0	51.0	100.0
				Week 24	59	69.1	9.46	68.0	50.0	92.0
				End of Trt.	84	69.3	9.42	68.5	50.0	92.0
		Xan.Low	84	Baseline	84	68.8	9.52	68.0	50.0	88.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.01
Summary of Vital Signs at Baseline and End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
AFTER STANDING FOR 1 MINUTE				Week 24	27	68.1	9.28	68.0	52.0	90.0
				End of Trt.	84	67.8	10.55	68.0	48.0	100.0
		Xan.High	84	Baseline	84	70.1	9.27	68.0	52.0	98.0
				Week 24	30	69.3	11.88	68.0	47.0	96.0
				End of Trt.	82	68.1	11.27	68.0	47.0	100.0
		Placebo	86	Baseline	85	75.5	12.68	76.0	56.0	133.0
				Week 24	59	72.8	8.98	74.0	52.0	88.0
				End of Trt.	84	73.5	9.09	74.0	52.0	96.0
		Xan.Low	84	Baseline	84	73.5	10.59	72.0	53.0	100.0
				Week 24	27	72.1	9.53	74.0	52.0	88.0
				End of Trt.	84	73.0	10.84	73.0	51.0	104.0
		Xan.High	84	Baseline	84	75.0	10.89	72.0	56.0	104.0
				Week 24	30	73.4	11.93	72.0	54.0	98.0
				End of Trt.	82	72.6	11.11	71.0	52.0	100.0
AFTER STANDING FOR 3 MINUTES		Placebo	86	Baseline	85	74.6	11.94	74.0	54.0	134.0
				Week 24	59	72.8	8.73	74.0	56.0	88.0
				End of Trt.	84	73.4	9.08	74.0	56.0	98.0
		Xan.Low	84	Baseline	84	72.3	10.99	70.0	51.0	104.0
				Week 24	27	70.7	10.78	72.0	52.0	96.0
				End of Trt.	83	71.6	10.42	72.0	52.0	97.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.01
Summary of Vital Signs at Baseline and End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
		Xan.High	84	Baseline	84	74.0	10.76	72.0	52.0	100.0
				Week 24	30	72.4	11.92	71.5	54.0	96.0
				End of Trt.	81	71.8	10.76	70.0	54.0	106.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.02
Summary of Vital Signs **Change from Baseline** at End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
Systolic Blood Pressure (mmHg)	AFTER LYING DOWN FOR 5 MINUTES	Placebo	86	Week 24	58	-2.1	14.73	-4.0	-28.0	50.0
				End of Trt.	83	-2.0	16.76	-4.0	-32.0	50.0
		Xan.Low	84	Week 24	27	-0.3	17.19	2.0	-48.0	30.0
				End of Trt.	84	-3.1	16.57	-2.0	-48.0	34.0
		Xan.High	84	Week 24	30	-5.6	17.18	-7.0	-36.0	26.0
				End of Trt.	82	-5.8	14.48	-8.0	-36.0	29.0
	AFTER STANDING FOR 1 MINUTE	Placebo	86	Week 24	58	-1.7	16.87	0.0	-32.0	40.0
				End of Trt.	83	-1.6	17.76	0.0	-46.0	48.0
		Xan.Low	84	Week 24	27	-0.1	17.73	-1.0	-30.0	48.0
				End of Trt.	84	-2.8	17.40	-1.5	-52.0	48.0
		Xan.High	84	Week 24	30	-6.3	19.49	-9.0	-36.0	42.0
				End of Trt.	82	-6.7	16.98	-8.0	-44.0	42.0
	AFTER STANDING FOR 3 MINUTES	Placebo	86	Week 24	58	-1.0	15.80	-3.5	-36.0	38.0
				End of Trt.	83	-2.5	16.61	-4.0	-40.0	48.0
		Xan.Low	84	Week 24	27	-0.1	16.20	0.0	-30.0	30.0
				End of Trt.	83	-3.5	16.51	-4.0	-52.0	60.0
		Xan.High	84	Week 24	30	-9.0	16.88	-8.0	-40.0	30.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.02
Summary of Vital Signs Change from Baseline at End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
				End of Trt.	81	-8.3	15.21	-8.0	-40.0	30.0
Diastolic Blood Pressure (mmHg)	AFTER LYING DOWN FOR 5 MINUTES	Placebo	86	Week 24	58	-0.8	10.82	-0.5	-18.0	41.0
				End of Trt.	83	-1.0	10.99	0.0	-34.0	41.0
		Xan.Low	84	Week 24	27	-0.9	7.71	-2.0	-20.0	16.0
				End of Trt.	84	-2.0	8.80	-2.0	-30.0	18.0
		Xan.High	84	Week 24	30	-2.2	9.20	-1.0	-20.0	21.0
				End of Trt.	82	-3.1	8.79	-4.0	-24.0	21.0
	AFTER STANDING FOR 1 MINUTE	Placebo	86	Week 24	58	-2.3	10.08	-4.0	-23.0	24.0
				End of Trt.	83	-2.8	10.17	-2.0	-34.0	24.0
		Xan.Low	84	Week 24	27	1.0	7.30	2.0	-20.0	18.0
				End of Trt.	84	-1.2	8.93	0.0	-30.0	20.0
		Xan.High	84	Week 24	30	-2.3	10.85	-7.0	-18.0	22.0
				End of Trt.	82	-2.1	12.10	-2.0	-34.0	28.0
	AFTER STANDING FOR 3 MINUTES	Placebo	86	Week 24	58	-2.3	9.56	-3.5	-22.0	20.0
				End of Trt.	83	-2.7	9.36	-2.0	-30.0	20.0
		Xan.Low	84	Week 24	27	-1.6	8.29	0.0	-20.0	10.0
				End of Trt.	83	-1.8	9.69	-1.0	-24.0	38.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.02
Summary of Vital Signs Change from Baseline at End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
Pulse (bpm)	AFTER LYING DOWN FOR 5 MINUTES	Xan.High	84	Week 24	30	-2.1	9.77	-3.5	-20.0	16.0
				End of Trt.	81	-2.6	10.81	-2.0	-40.0	27.0
		Placebo	86	Week 24	58	-0.3	8.77	-1.0	-24.0	24.0
				End of Trt.	83	-0.9	8.69	-1.0	-24.0	24.0
		Xan.Low	84	Week 24	27	-1.6	10.53	0.0	-24.0	25.0
				End of Trt.	84	-1.0	11.12	-0.5	-24.0	32.0
	AFTER STANDING FOR 1 MINUTE	Xan.High	84	Week 24	30	-2.0	11.16	-2.0	-34.0	20.0
				End of Trt.	82	-1.7	8.95	-2.0	-34.0	20.0
		Placebo	86	Week 24	58	-1.7	11.72	0.5	-53.0	18.0
				End of Trt.	83	-1.8	11.05	-1.0	-53.0	20.0
		Xan.Low	84	Week 24	27	-1.3	9.05	0.0	-20.0	12.0
				End of Trt.	84	-0.5	11.69	0.0	-24.0	34.0
	AFTER STANDING FOR 3 MINUTES	Xan.High	84	Week 24	30	-1.8	13.41	-3.0	-36.0	20.0
				End of Trt.	82	-2.1	10.43	-1.5	-36.0	22.0
		Placebo	86	Week 24	58	-1.5	10.47	0.0	-46.0	14.0
				End of Trt.	83	-1.0	9.89	0.0	-46.0	18.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Table 14-7.02
Summary of Vital Signs Change from Baseline at End of Treatment

Measure	Position	Treatment	N	Planned Relative Time	n	Mean	SD	Median	Min.	Max.
Xan.Low		84		Week 24	27	-2.1	8.77	-2.0	-20.0	16.0
				End of Trt.	83	-0.7	10.73	-1.0	-22.0	29.0
Xan.High		84		Week 24	30	-2.7	11.12	-2.0	-40.0	14.0
				End of Trt.	81	-1.9	9.49	-1.0	-40.0	20.0

End of treatment is the last on-treatment assessment of the specified vital sign (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Protocol: CDISCPILOT01
Population: Safety

Page 1 of 1

Table 14-7.03
Summary of **Weight Change** from Baseline at End of Treatment

Measure	Treatment	N	Planned Relative	n	Mean	SD	Median	Min.	Max.
			Time						
Weight (kg)	Placebo	86	Baseline	86	62.8	12.77	60.6	34.0	86.2
			Week 24	59	63.2	12.58	63.5	34.0	86.6
			End of Trt.	84	63.3	12.66	64.0	34.0	86.6
	Xan.Low	84	Baseline	83	67.3	14.13	64.9	45.4	106.1
			Week 24	27	67.4	14.07	62.6	45.5	106.1
			End of Trt.	84	66.7	14.32	65.9	41.7	106.1
	Xan.High	84	Baseline	84	70.0	14.65	69.2	41.7	108.0
			Week 24	30	71.1	15.82	68.7	49.9	105.7
			End of Trt.	81	69.7	14.00	70.3	42.2	105.7
Weight Change from Baseline	Placebo	86	Week 24	59	0.1	2.30	0.0	-4.5	8.2
			End of Trt.	84	0.2	2.05	0.0	-4.5	8.2
	Xan.Low	84	Week 24	27	-0.3	2.04	0.0	-5.4	3.2
			End of Trt.	83	-0.4	2.41	0.0	-14.5	5.9
	Xan.High	84	Week 24	30	1.0	6.47	-0.2	-4.5	33.3
			End of Trt.	81	0.1	4.19	-0.4	-5.5	33.3

End of treatment is the last on-treatment assessment of weight (on or before the Week 24 visit).

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtvs.sas

21:06 Monday, June 26, 2006

Protocol: CDISCPILOT01

Page 1 of 2

Population: Safety


Table 14-7.04
Summary of Concomitant Medications (Number of Subjects)

Therapeutic class, n (%)	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)
Patients receiving at least one concomitant medication	77 (90%)	74 (88%)	78 (93%)
ALIMENTARY TRACT AND METABOLISM	12 (14%)	11 (13%)	9 (11%)
CALCIUM	7 (8%)	6 (7%)	3 (4%)
ALGELDRATE	2 (2%)	0	2 (2%)
LOPERAMIDE HYDROCHLORIDE	1 (1%)	1 (1%)	1 (1%)
METFORMIN HYDROCHLORIDE	1 (1%)	1 (1%)	0
NIZATIDINE	1 (1%)	1 (1%)	4 (5%)
CALCIUM CARBONATE	0	0	1 (1%)
CIMETIDINE	0	1 (1%)	0
SIMETICONE	0	2 (2%)	0
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	1 (1%)	0	1 (1%)
LEUPRORELIN ACETATE	1 (1%)	0	1 (1%)
BLOOD AND BLOOD FORMING ORGANS	0	1 (1%)	0
FERROUS SULFATE	0	1 (1%)	0
CARDIOVASCULAR SYSTEM	12 (14%)	12 (14%)	7 (8%)
AMLODIPINE	8 (9%)	1 (1%)	2 (2%)
FUROSEMIDE	2 (2%)	2 (2%)	1 (1%)
NIFEDIPINE	2 (2%)	0	0
DOXAZOSIN MESILATE	1 (1%)	2 (2%)	1 (1%)
DIGOXIN	0	3 (4%)	2 (2%)
DILTIAZEM HYDROCHLORIDE	0	0	1 (1%)
FELODIPINE	0	1 (1%)	0
FLUVASTATIN	0	2 (2%)	0
LOSARTAN POTASSIUM	0	2 (2%)	0
DERMATOLOGICALS	0	0	1 (1%)

Table 14-7.04
Summary of Concomitant Medications (Number of Subjects)

Therapeutic class, n (%)	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)
CLOBETASOL PROPIONATE	0	0	1 (1%)
GENITO URINARY SYSTEM AND SEX HORMONES	6 (7%)	10 (12%)	5 (6%)
ESTROGENS CONJUGATED	6 (7%)	10 (12%)	5 (6%)
NERVOUS SYSTEM	23 (27%)	14 (17%)	8 (10%)
ACETYLSALICYLIC ACID	21 (24%)	11 (13%)	6 (7%)
ALPRAZOLAM	1 (1%)	0	0
DONEPEZIL HYDROCHLORIDE	1 (1%)	2 (2%)	2 (2%)
SUMATRIPTAN	1 (1%)	0	0
HALOPERIDOL	0	1 (1%)	0
PAROXETINE HYDROCHLORIDE	0	1 (1%)	0
RESPIRATORY SYSTEM	4 (5%)	1 (1%)	4 (5%)
SALBUTAMOL SULFATE	2 (2%)	1 (1%)	0
GUAIFENESIN	1 (1%)	0	0
IPRATROPIUM BROMIDE	1 (1%)	0	0
NAPROXEN SODIUM	1 (1%)	0	3 (4%)
BUDESONIDE	0	0	1 (1%)
SYSTEMIC HORMONAL PREPARATIONS, EXCL.	2 (2%)	13 (15%)	8 (10%)
HYDROCORTISONE	2 (2%)	13 (15%)	8 (10%)
UNCODED	74 (86%)	70 (83%)	77 (92%)
UNCODED	74 (86%)	70 (83%)	77 (92%)

Figure 14-1
Time to Dermatologic Event by Treatment Group



Note: Dermatologic events were identified as adverse events associated with skin conditions such as rash, pruritus, dermatitis. A full list of adverse event terms is presented in the final study report.

Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\kmfigure.sas

21:45 Monday, June 26, 2006